QuidelOrtho 10-K 27 Feb 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 21, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	QUIDEL CORP /DE/
Entity Central Index Key	353,569
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	QDEL
Amendment Flag	false
Entity Common Stock, Shares Outstanding		34,852,455
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 747,331,220

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 36,086	$ 169,508
Accounts receivable, net	67,046	24,990
Inventories	67,078	26,045
Assets Held-for-sale, Not Part of Disposal Group, Current	146,644	0
Prepaid expenses and other current assets	14,375	4,851
Total current assets	331,229	225,394
Property, plant and equipment, net	61,585	50,858
Goodwill	337,028	83,834
Intangible assets, net	203,827	27,639
Other non-current assets	1,582	525
Total assets	935,251	388,250
Current liabilities:
Accounts payable	27,279	16,047
Accrued payroll and related expenses	15,926	9,642
Current portion of contingent consideration	6,293	2,826
Current portion of deferred consideration	46,000	0
Current portion of Revolving Credit Facility	10,000	0
Current portion of long-term debt	10,184	0
Other current liabilities	12,666	5,097
Total current liabilities	128,348	33,612
Convertible Senior Notes	149,868	144,340
Convertible Senior Notes	227,394	0
Deferred consideration - non-current	177,158	0
Contingent consideration - non-current	18,008	2,349
Deferred tax liability - non-current	430	58
Other non-current liabilities	6,941	7,261
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at December 31, 2017 and 2016	0	0
Common stock, $.001 par value per share; 97,500 shares authorized; 34,540 and 32,897 shares issued and outstanding at December 31, 2017 and 2016, respectively	35	33
Additional paid-in capital	239,489	204,905
Accumulated other comprehensive loss	0	(53)
Accumulated deficit	(12,420)	(4,255)
Total stockholders’ equity	227,104	200,630
Total liabilities and stockholders’ equity	$ 935,251	$ 388,250

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	97,500,000	50,000,000
Common stock, shares issued	32,897,000	33,323,000
Common stock, shares outstanding	32,897,000	33,323,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Total revenues	$ 277,743	$ 191,603	$ 196,129
Cost of sales	121,601	79,872	78,029
Gross profit	156,142	111,731	118,100
Research and development	33,644	38,672	35,514
Sales and marketing	67,248	50,436	50,401
General and administrative	29,192	26,351	27,057
Acquisition and integration costs	16,506	711	2,390
Total operating expenses	146,590	116,170	115,362
Operating income (loss)	9,552	(4,439)	2,738
Interest expense, net	(17,588)	(11,760)	(12,035)
Loss before taxes	(8,036)	(16,199)	(9,297)
Provision (benefit) for income taxes	129	(2,391)	(3,218)
Net loss	$ (8,165)	$ (13,808)	$ (6,079)
Basic and diluted loss per share	$ (0.24)	$ (0.42)	$ (0.18)
Shares used in basic and diluted per share calculation	33,734	32,708	34,104

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (8,165)	$ (13,808)	$ (6,079)
Other comprehensive income, net of tax
Changes in cumulative translation adjustment	53	(22)	(2)
Comprehensive loss	$ (8,112)	$ (13,830)	$ (6,081)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive income (loss) [Member]	Retained earnings [Member]
Beginning Balance at Dec. 31, 2014	$ 245,011	$ 34	$ 229,374	$ (29)	$ 15,632
Beginning Balance, shares at Dec. 31, 2014		34,433
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	3,318	$ 0	3,318	0
Issuance of common stock under equity compensation plans, shares		308
Issuance of common stock under equity compensation plans	571		571	0	0
Tax impact from the issuance of convertible senior notes	6,791		6,791
Stock-based compensation expense	(30,934)		(30,933)
Repurchase of common stock, shares		(1,418)
Repurchases of common stock	(2)			(2)
Net loss	(6,079)				(6,079)
Ending Balance at Dec. 31, 2015	218,676	$ 33	209,121	(31)	9,553
Ending Balance, shares at Dec. 31, 2015		33,323
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	9,365	$ 0	9,365
Issuance of common stock under equity compensation plans, shares		755
Tax impact from the issuance of convertible senior notes	7,134		7,134
Stock-based compensation expense	(20,168)	$ 0	(20,168)
Repurchase of common stock, shares		(1,181)
Repurchases of common stock	(22)			(22)
Net loss	(13,808)				(13,808)
Ending Balance at Dec. 31, 2016	200,630	$ 33	204,905	(53)	(4,255)
Ending Balance, shares at Dec. 31, 2016		32,897
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	26,079	$ 2	26,077
Issuance of common stock under equity compensation plans, shares		1,669
Tax impact from the issuance of convertible senior notes	9,048		9,048
Stock-based compensation expense	(541)	$ 0	(541)
Repurchase of Convertible Senior Notes	547
Repurchase of common stock, shares		(26)
Repurchases of common stock	53			53
Net loss	(8,165)
Ending Balance at Dec. 31, 2017	$ 227,104	$ 35	$ 239,489	$ 0	$ (12,420)
Ending Balance, shares at Dec. 31, 2017		34,540

Consolidated Statements of Cash

Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
OPERATING ACTIVITIES
Net loss	$ (8,165)	$ (13,808)	$ (6,079)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation, amortization and other	30,762	22,796	23,386
Stock-based compensation expense	9,061	7,986	7,419
Amortization of debt discount and deferred issuance costs	6,022	5,891	5,664
Change in fair value of acquisition contingencies	(81)	(485)	(88)
Accretion of interest on deferred consideration		0	0
Amortization of inventory step-up to fair value	10,950	0	0
Change in fair value of acquisition contingencies	365	(2,603)	(4,027)
Gain on extinguishment of Convertible Senior Notes	0	(421)	0
Excess tax benefit from share-based compensation
Accounts receivable	(42,052)	(6,265)	16,060
Inventories	362	859	(1,637)
Prepaid expenses and other current and non-current assets	(9,113)	(552)	(1,039)
Restricted cash	0	63	3,064
Accounts payable	12,956	4,323	(3,082)
Accrued payroll and related expenses	7,130	(375)	1,061
Deferred grant revenue	0	(3,658)	(2,672)
Other current and non-current liabilities	6,904	(1,936)	(1,150)
Net cash provided by operating activities	27,709	11,815	36,880
INVESTING ACTIVITIES
Acquisitions of property, equipment and intangibles	(17,510)	(11,909)	(17,032)
Acquisition of other businesses, net of cash acquired	(14,451)	(5,061)	0
Acquisition of Triage and BNP Businesses	(399,798)	0	0
Net cash used for investing activities	(431,759)	(16,970)	(17,032)
FINANCING ACTIVITIES
Proceeds from issuance of Term Loan	245,000	0	0
Proceeds from issuance of Revolving Credit Facility	10,000	0	0
Proceeds from issuance of common stock	25,426	8,575	2,911
Payments of debt issuance costs	(8,682)	0	(365)
Payments on lease obligation	(98)	(540)	(509)
Repurchases of common stock	(541)	(20,168)	(30,934)
Repurchases of Convertible Senior Notes	0	(4,459)	0
Payments on acquisition contingencies	(497)	(207)	(129)
Payment for acquisition holdback	0	0	(229)
Net cash provided by (used for) financing activities	270,608	(16,799)	(29,255)
Effect of exchange rate changes on cash	20	(9)	(17)
Net decrease in cash and cash equivalents	(133,422)	(21,963)	(9,424)
Cash and cash equivalents, beginning of period	169,508	191,471	200,895
Cash and cash equivalents, at end of period	36,086	169,508	191,471
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for interest	9,137	6,488	6,998
Cash paid during the period for income taxes	1,274	490	1,922
NON-CASH INVESTING ACTIVITIES
Purchase of property, equipment and intangibles by incurring current liabilities	1,446	3,280	239
NON-CASH FINANCING ACTIVITIES
Decrease of accrued payroll and related expenses upon issuance of common stock	903	539	408
Receivable for stock option exercises	$ 0	251	0
Deferred consideration for acquisition of BNP Business		$ 0	$ 0

Company Operations and Summary

Company Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition—
Company Operations and Summary of Significant Accounting Policies	Company Operations and Summary of Significant Accounting Policies Quidel Corporation (the “Company”) commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets rapid diagnostic testing solutions. These diagnostic tests can be categorized in the following product categories: Rapid Immunoassay, Cardiac Immunoassay, Specialized Diagnostic Solutions and Molecular Diagnostic Solutions. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics and wellness screening centers. The Company markets its products through a network of distributors and a direct sales force and temporary transition service arrangements entered into with Abbott Laboratories in connection with the acquisition of the Triage and BNP Businesses. The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the U.S. Consolidation— The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. The Company invests its cash equivalents primarily in money market funds and commercial paper. Cash equivalents are maintained with high quality institutions. Accounts Receivable— The Company sells its products directly to hospitals and reference laboratories as well as to distributors in the U.S. and sells directly to hospitals and labs and through distribution internationally (see Note 9 ). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company’s reserves primarily consist of amounts related to cash discounts and contract rebates. The balance of accounts receivable is net of reserves of $12.3 million and $7.2 million at December 31, 2017 and 2016 , respectively. Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consists principally of trade accounts receivable. The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable. Inventories— Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory on a quarterly basis for excess, obsolete and impaired inventory and makes appropriate dispositions as obsolete stock is identified. Assets Held for Sale— Assets to be disposed that meet the held for sale criteria are reported at the lower of their carrying amount and fair value, less costs to sell, and are no longer depreciated. Property, Plant and Equipment— Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets ( three to 15 years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the estimated useful lives of the assets. Goodwill and Intangible Assets— Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized. The capitalized cost is amortized on a straight-line basis over the estimated product life or on the ratio of current revenues to total projected product revenues, whichever is greater. Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 3 for additional discussion of the Convertible Senior Notes issued in December 2014. Revenue Recognition— The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates and discounts are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Revenues from product sales are recorded upon passage of title and risk of loss to the customer. Passage of title to the product and recognition of revenue occurs upon delivery to the customer when sales terms are free on board (“FOB”) destination and at the time of shipment when the sales terms are FOB shipping point and there is no right of return. A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property and equipment. The instrument is depreciated on a straight-line basis over the life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Operations. The reagent rental agreements represent one unit of accounting as the instrument and consumables (reagents) are interdependent in producing a diagnostic result and neither has a stand-alone value with respect to these agreements. No revenue is recognized at the time of instrument placement. All revenue is recognized when the title and risk of loss for the diagnostic kits have passed to the customer. Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. From time to time, the Company earns income from grants for research and commercialization activities. For the years ended December 31, 2016 and 2015 , the Company recognized $6.5 million and $5.1 million as grant revenue, respectively, related to the Bill and Melinda Gates Foundation to develop, manufacture and validate a quantitative, low-cost, nucleic acid assay for HIV drug treatment monitoring on the integrated Savanna MDx platform for use in limited resource settings. Cash payments received were restricted as to use until expenditures contemplated in the grant were incurred or committed. As of December 31, 2016, all payment related milestones have been achieved and all of the grant revenue of $20.9 million was fully recognized. As such, the Company recognized no grant revenue during the twelve months ended December 31, 2017. Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred. Product Shipment Costs— Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Operations. Shipping and handling costs were $3.7 million , $3.8 million and $3.9 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. Advertising Costs— Advertising costs are expensed as incurred. Advertising costs were $0.5 million , $0.3 million and $0.7 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. Deferred Rent— The Company enters into lease arrangements for office space under non-cancelable operating leases. Certain of the operating lease agreements contain rent escalation provisions, which are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the leased property for purposes of recognizing lease expense on a straight-line basis over the term of the lease. The Company does not assume renewals in the determination of the lease term unless the renewals are deemed to be reasonably assured at lease inception. The difference between rent expense and amounts paid under the Company's lease agreements are recorded as deferred rent. Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense. Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in Accounting Standards Codification (“ASC”) Topic 820 , Fair Value Measurements and Disclosures, which requires that the valuation of assets and liabilities subject to fair value measurements be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. Reclassifications — The Company recorded reclassifications of acquisition and integration costs totaling $0.7 million and $2.4 million for years ended December 31, 2016 and 2015, respectively, from general and administrative expense as previously reported in the Consolidated Statements of Operations to conform to current year presentation. The Company believes these reclassifications provide greater clarity and insight into the consolidated financial statements for the periods presented. The Company also recorded reclassifications of $6.5 million and $6.3 million for the years ended December 31, 2016 and 2015, respectively, from amortization of intangible assets from acquired business and technology to cost of sales expense as previously reported in the Consolidated Statements of Operations. In addition, the Company recorded reclassifications of $2.6 million and $2.5 million for the years ended December 31, 2016 and 2015, respectively, from amortization of intangible assets from acquired business and technology to sales and marketing expense to conform to current year presentation. These reclassifications did not impact the net loss as previously reported or any prior amounts reported on the Consolidated Balance Sheets, Statements of Cash Flows or Statements of Comprehensive Loss. Product Warranty —The Company generally sells products with a limited product warranty and certain limited indemnifications. Due to product testing, the short time between product shipment and the detection and correction of product failures and a low historical rate of payments on indemnification claims, the historical activity and the related expense were not significant for the fiscal years presented. Stock-Based Compensation —Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. The fair value of restricted stock units is determined based on the closing market price of the Company’s common stock on the grant date. Compensation expense for time-based restricted stock units is measured at the grant date and recognized ratably over the vesting period. For purposes of measuring compensation expense for performance-based restricted stock units, the amount of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with the performance-based restricted stock units requires judgment in assessing the probability of meeting the performance goals. This may result in significant expense recognition in the period in which the performance goals are met or when achievement of the goals is deemed probable or may result in the reversal of previously recognized stock-based compensation expense if the performance criteria are deemed not probable of being met. Computation of (Loss) Earnings Per Share —For the years ended December 31, 2017 , 2016 and 2015 , basic loss per share was computed by dividing net loss by the weighted-average number of common shares outstanding, including restricted stock units vested during the period. Diluted earnings per share (“EPS”) reflects the potential dilution that could occur if the earnings were divided by the weighted-average number of common shares and potentially dilutive common shares from outstanding stock options, unvested restricted stock units and the 3.25% Convertible Senior Notes due 2020 (“Convertible Senior Notes”). Potentially dilutive common shares from outstanding stock options and unvested restricted stock units are determined using the average share price for each period under the treasury stock method. Comprehensive Loss —Comprehensive loss includes unrealized gains and losses which are related to the cumulative translation adjustments excluded from the Company’s Consolidated Statements of Operations. Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Accounting Periods —Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ends are December 31, 2017, January 1, 2017 and January 3, 2016. For ease of reference, the calendar quarter end dates are used herein. Recent Accounting Pronouncements —In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance codified in Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition ("ASC 605"). The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current authoritative guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The FASB has issued several amendments to the new standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations. ASU 2014-09 and all subsequent amendments (collectively, the “ASC 606”) will be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. The Company will adopt ASC 606 on January 1, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. Our evaluation of our contracts subject to this standard is substantially complete and based on procedures completed to date, we do not expect the application of the new standard to these contracts to have a material impact to our Consolidated Statements of Operations or Balance Sheets at initial implementation. We are also evaluating the new disclosures required by the standard to determine what additional information will need to be disclosed. In February 2016, the FASB issued guidance codified in ASU 2016-02 (Topic 842), Leases . The guidance requires a lessee to recognize a lease liability for the obligation to make lease payments and a right-to-use asset representing the right to use the underlying asset for the lease term on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018 including interim periods within those years. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2019. In January 2017, the FASB issued guidance codified in ASU 2017-04, Intangibles-Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). Under this new guidance, an entity will no longer determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Instead, an entity will compare the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. The guidance is effective for fiscal years beginning after December 15, 2019 including interim periods therein. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2020. In March 2016, the FASB issued guidance codified in ASU 2016-09 (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) . This guidance includes provisions to simplify several aspects of accounting for share-based payment transactions, including income tax consequences, accounting for forfeitures, classification of awards as either equity or liability and classification on the statement of cash flows. ASU 2016-09 includes a requirement that the tax effect related to the settlement of share-based awards be recorded within income tax expense or benefit in the income statement. The simplification of income tax accounting for share-based payment transactions also impacts the computation of weighted-average diluted shares outstanding under the treasury stock method. The Company adopted ASU 2016-09 in the first quarter of 2017 and the impact of the adoption resulted in the following: • Upon adoption, the balance of the unrecognized excess tax benefits of $1.8 million was recorded as an increase to deferred tax assets and a corresponding increase to the valuation allowance, resulting in no impact to retained earnings. • Excess tax benefits from share-based arrangements are to be classified within cash flow from operating activities, rather than as cash flow from financing activities. The Company applied this provision on a retrospective basis and the prior period statement of cash flows was adjusted. This adoption did not have a material impact on the Company’s cash flows. • The Company elected to continue to estimate the number of awards expected to be forfeited and adjust the estimate when appropriate, as is currently required. This adoption did not have a material impact on the Company’s consolidated results of operations, financial condition or cash flows. • There was no material impact on the computation of weighted-average diluted shares outstanding.

Balance Sheet Account Details (

Balance Sheet Account Details (Notes)	12 Months Ended
	Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]
Goodwill Disclosure [Text Block]	$ 253.2 million
Supplemental Balance Sheet Disclosures [Text Block]	Balance Sheet Account Details Inventories Inventories consisted of the following, net of immaterial excess and obsolete reserves, at December 31, 2017 and 2016 (in thousands): December 31, 2017 2016 Raw materials $ 22,252 $ 9,297 Work-in-process (materials, labor and overhead) 22,813 7,990 Finished goods (materials, labor and overhead) 22,013 8,758 Total inventories $ 67,078 $ 26,045 Property, Plant and Equipment The following is a summary of property, plant and equipment (in thousands): December 31, 2017 2016 Equipment, furniture and fixtures $ 75,728 $ 61,972 Building and improvements 34,994 34,243 Leased instruments 32,458 24,014 Land 1,080 1,080 Total property, plant and equipment, gross 144,260 121,309 Less: accumulated depreciation and amortization (82,675 ) (70,451 ) Total property, plant and equipment, net $ 61,585 $ 50,858 The equipment, furniture and fixtures category above includes construction in progress and instruments that have not been placed at a customer under a lease agreement. These items will be reclassified when the assets are placed in service. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $14.6 million , $13.4 million and $12.7 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. Maintenance and minor repairs are charged to operations as incurred. Goodwill and Intangible Assets The Company had goodwill of $337.0 million as of December 31, 2017 , which increased by $ 253.2 million as compared to $83.8 million as of December 31, 2016 due to the Company's acquisition of the cardiovascular and toxicology Triage® MeterPro business (“Triage Business”) and the Triage® BNP Test for the Beckman Coulter Access Family of Immunoassay Systems business (the “BNP Business”). The Triage Business and the BNP Business are collectively referred to as the “Triage and BNP Businesses.” On October 6, 2017, the Company acquired the Triage and BNP Businesses from Alere Inc. ("Alere"). As part of this acquisition, the Company identified and recorded $ 115.0 million in customer relationships, $52.4 million in purchased technology and $ 17.5 million in trademarks. Refer to Note 12 for additional details regarding the acquisition and the purchase price allocation. On May 16, 2017, the Company acquired the InflammaDry® and AdenoPlus® diagnostic businesses from RPS Diagnostics, a developer and manufacturer of rapid, point-of-care (“POC”) diagnostic tests for the eye health and primary care markets, for approximately $13.7 million in cash. The purchase price has been allocated as follows: $6.1 million to purchased technology and $7.6 million to goodwill. The acquisition has been accounted for in conformity with ASC Topic 805, Business Combinations . The InflammaDry and AdenoPlus products are rapid, lateral-flow based, POC products for the detection of infectious and inflammatory diseases and conditions of the eye. Revenues for these products are reflected in the Company’s Rapid Immunoassay revenue category. Amortizable intangible assets consisted of the following (dollar amounts in thousands): December 31, 2017 December 31, 2016 Description Weighted-average useful life (years) Gross assets Accumulated amortization Net Gross assets Accumulated amortization Net Purchased technology 9.1 112,100 (49,614 ) 62,486 53,600 (41,369 ) 12,231 Customer relationships 7.0 122,404 (10,960 ) 111,444 7,157 (5,928 ) 1,229 License agreements 9.9 6,515 (3,980 ) 2,535 6,009 (3,222 ) 2,787 Patent and trademark costs 10.8 28,740 (4,917 ) 23,823 11,240 (3,522 ) 7,718 Software development costs 5 6,630 (3,091 ) 3,539 6,000 (2,326 ) 3,674 Total amortizable intangible assets $ 276,389 $ (72,562 ) $ 203,827 $ 84,006 $ (56,367 ) $ 27,639 Amortization expense related to the capitalized software costs was $0.8 million , $0.5 million and $0.6 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. Amortization expense (including capitalized software costs) was $16.1 million , $9.5 million and $10.2 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands): For the years ending December 31, Amortization expense 2018 $ 28,799 2019 27,542 2020 27,144 2021 26,996 2022 26,472 Thereafter 66,874 Total $ 203,827 Other current liabilities The following is a summary of other current liabilities (in thousands): December 31, 2017 2016 Customer incentives $ 7,165 $ 3,766 Accrued interest 442 227 Other 5,059 1,104 Total other current liabilities $ 12,666 $ 5,097

Debt

Debt	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt	Debt 3.25% Convertible Senior Notes due 2020 In December 2014, the Company issued $172.5 million aggregate principal amount of 3.25% Convertible Senior Notes due 2020. Debt issuance costs of approximately $5.1 million were primarily comprised of underwriters fees, legal, accounting, and other professional fees of which $4.2 million were capitalized and are recorded as a reduction to long-term debt and are being amortized using the effective interest method to interest expense over the six -year term of the Convertible Senior Notes. The remaining $0.9 million of debt issuance costs were allocated as a component of equity in additional paid-in capital. Deferred issuance costs related to the Convertible Senior Notes were $2.1 million and $2.8 million as of December 31, 2017 and 2016 , respectively. The holders of the Convertible Senior Notes may surrender their notes for conversion, subject to specified circumstances, into cash, shares of common stock, or a combination of cash and shares of common stock, at the election of the Company, based on an initial conversion rate, subject to adjustment, of 31.1891 shares per $1,000 principal amount of the Convertible Senior Notes (which represents an initial conversion price of approximately $32.06 per share) up until the business day immediately preceding September 15, 2020. This conversion may, in the discretion of the holder, occur in the following circumstances and to the following extent: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2015, if the last reported sales price of the Company's common stock, for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price of the notes in effect on each applicable trading day; (2) during the five consecutive business day period following any five consecutive trading day period in which the trading price per $1,000 principal amount of the Convertible Senior Note for each such trading day was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such day; or (3) upon the occurrence of specified events described in the indenture for the Convertible Senior Notes. On or after September 15, 2020 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their notes for conversion at any time, regardless of the foregoing circumstances. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, or the conversion value during the 25 -day observation period as described in the indenture for the Convertible Senior Notes. The conversion value is the sum of the daily conversion value, which is the product of the effective conversion rate divided by 25 days and the daily volume weighted-average price (“VWAP”) of the Company’s common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. The Company pays 3.25% interest per annum on the principal amount of the Convertible Senior Notes semi-annually in arrears in cash on June 15 and December 15 of each year. The effective interest rate during fiscal year 2017 was 6.6% . The Convertible Senior Notes mature on December 15, 2020. During the year ended December 31, 2017 , the Company recorded total interest expense of $11.0 million related to the Convertible Senior Notes of which $5.5 million related to the amortization of the debt discount and issuance costs and $5.4 million related to the coupon due semi-annually. During the year ended December 31, 2016 , the Company recorded total interest expense of $10.9 million related to the Convertible Senior Notes of which $5.4 million related to the amortization of the debt discount and issuance costs and $5.5 million related to the coupon due semi-annually. During the year ended December 31, 2015 , the Company recorded total interest expense of $10.9 million related to the Convertible Senior Notes of which $5.3 million related to the amortization of the debt discount and issuance costs and $5.6 million related to the coupon due semi-annually. If a fundamental change, as defined in the indenture for the Convertible Senior Notes, such as certain acquisitions, mergers, or a liquidation of the Company, occurs prior to the maturity date, subject to certain limitations, holders of the Convertible Senior Notes may require the Company to repurchase all or a portion of their Convertible Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the repurchase date. The Company accounts separately for the liability and equity components of the Convertible Senior Notes in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance requires the carrying amount of the liability component to be estimated by measuring the fair value of a similar liability that does not have an associated conversion feature. Because the Company had no outstanding non-convertible public debt, the Company determined that senior, unsecured corporate bonds traded on the market represent a similar liability to the Convertible Senior Notes without the conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry with similar credit ratings and with similar maturity, the Company estimated the implied interest rate of its Convertible Senior Notes to be 6.9% , assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, which were defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Convertible Senior Notes, which resulted in a fair value of the liability component of $141.9 million upon issuance, calculated as the present value of implied future payments based on the $172.5 million aggregate principal amount. The $30.7 million difference between the cash proceeds of $172.5 million and the estimated fair value of the liability component was recorded in additional paid-in capital, net of tax and issuance costs, as the Convertible Senior Notes were not considered redeemable. In the first quarter of 2016, the Company repurchased and retired $5.2 million in principal amount of the outstanding Convertible Senior Notes. The aggregate cash used for the transaction was $4.5 million . The repurchase resulted in a reduction in debt of $4.4 million and a reduction in additional paid-in capital of $0.5 million with a gain on extinguishment of Convertible Senior Notes of $0.4 million included in interest expense, net in the Consolidated Statements of Operations. The following table summarizes information about the equity and liability components of the Convertible Senior Notes (dollars in thousands). The fair values of the respective notes outstanding were measured based on quoted market prices: December 31, 2017 2016 Principal amount of Convertible Senior Notes outstanding $ 167,314 $ 167,314 Unamortized discount of liability component (15,356 ) (20,221 ) Unamortized deferred issuance costs (2,090 ) (2,753 ) Net carrying amount of liability component 149,868 144,340 Less: current portion — — Long-term debt $ 149,868 $ 144,340 Carrying value of equity component, net of issuance costs $ 29,211 $ 29,211 Fair value of outstanding Convertible Senior Notes $ 257,245 $ 165,223 Remaining amortization period of discount on the liability component 3 years 4 years Historically, the Company disclosed its intent, ability and policy to settle conversions of its Senior Convertible Notes through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the principal portion in shares of common stock or cash. This would have resulted in the “share amount” impacting diluted EPS. Based upon the use of funds to acquire the Triage and BNP Businesses, the Company has determined that it currently does not have the available funds to settle the principal in cash and as a result, may choose to settle both the principal and share amount using equity. As a result, both the “principal portion” and “share portion” will impact diluted EPS. This change in assessment had no impact on diluted EPS because the Company incurred a net loss for the year ended December 31, 2017 . As of December 31, 2017 , the if-converted value exceeded the principal amount of the Convertible Senior Notes by $1.5 million . As of December 31, 2016 and 2015 , the Convertible Senior Notes were not convertible and the if-converted value did not exceed the principal amount of the Convertible Senior Notes, therefore, there was no dilutive impact for the years ended December 31, 2016 and 2015 . Senior Credit Agreement On October 6, 2017, the Company entered into a Credit Agreement (the “Credit Agreement”), which provided the Company with a $245.0 million senior secured term loan facility (the “Term Loan”) and a $25.0 million Revolving Credit Facility ("Revolving Credit Facility") together (the “Senior Credit Facility”). The Term Loan and the Revolving Credit Facility will mature on October 6, 2022. On the closing date of the Credit Agreement, the Company borrowed the entire amount of the Term Loan and $10.0 million under the Revolving Credit Facility. The Company used the proceeds of the Term Loan along with its cash on hand, to pay (i) the consideration for the Triage Business and (ii) the fees and expenses incurred in connection with the acquisition of the Triage and BNP Businesses. The Credit Agreement includes an accordion feature that allows the facility to be increased by $50.0 million upon the satisfaction of certain conditions. The Financing is guaranteed by certain material domestic subsidiaries of the Company (the “Guarantors”) and is secured by liens on substantially all of the assets of the Company and the Guarantors, excluding real property and certain other types of excluded assets. Loans under the Credit Agreement bear interest at a rate equal to (i) the London Interbank Offered Rate (“LIBOR”) plus the “applicable rate” or (ii) the “base rate” (defined as the highest of (a) the Bank of America prime rate, (b) the Federal Funds rate plus one-half of one percent and (c) LIBOR plus one percent ) plus the “applicable rate.” The initial applicable rate is 2.50% per annum for base rate loans and 3.50% per annum for LIBOR rate loans, and thereafter will be determined in accordance with a pricing grid based on the Company’s Consolidated Leverage Ratio (as defined in the Credit Agreement) ranging from 2.50% to 3.50% per annum for LIBOR rate loans and from 1.50% to 2.50% per annum for base rate loans. In addition, the Company will pay a commitment fee on the unused portion of the Credit Agreement based on the Company’s Consolidated Leverage Ratio ranging from 0.10% to 0.50% per annum. The Term Loan is subject to quarterly amortization of the principal amount on the last business day of each fiscal quarter of the Company (commencing on March 30, 2018) in such amounts as are set forth in the Credit Agreement. The Term Loan and the Revolving Credit Facility will mature on October 6, 2022, provided that if any of Convertible Senior Notes remain outstanding on the date that is 91 days prior to the maturity date of the Convertible Senior Notes and the Company has not satisfied certain Refinancing Conditions, then the maturity date for the Term Loan and the Revolving Credit Facility will be the date that is 91 days prior to the maturity date of the Convertible Senior Notes. The Company must prepay loans outstanding under the Credit Agreement in an amount equal to 50% of Excess Cash Flow (as defined in the Credit Agreement) for each fiscal year (commencing with fiscal 2018) less any amount voluntarily prepaid during such fiscal year, but only if the Consolidated Senior Secured Leverage Ratio (as defined in the Credit Agreement) as of the last day of such fiscal year is greater than or equal to 1.25 to 1.00. The Company must also prepay loans outstanding under the Credit Agreement in an amount equal to 100% of the Net Cash Proceeds (as defined in the Credit Agreement) from (i) certain property dispositions and (ii) the receipt of certain other amounts not in the ordinary course of business, in each case, if not reinvested within a specified time period as contemplated in the Credit Agreement, and with a carve out of up to 30% of the Net Cash Proceeds of the contemplated sale leaseback transaction relating to the Company’s Summers Ridge property to the extent the excluded amounts are used for specified purposes. The Credit Agreement contains affirmative and negative covenants that are customary for credit agreements of this nature. The negative covenants include, among other things, limitations on asset sales, mergers, indebtedness, liens, investments and transactions with affiliates. The Credit Agreement contains two financial covenants: (i) a maximum Consolidated Leverage Ratio as of the last day of each fiscal quarter for the most recently completed four fiscal quarters of (a) 5.00 to 1.00 for the fiscal quarter ending December 31, 2017, (b) 4.25 to 1.00 for the fiscal quarters ending March 31, 2018 through December 31, 2018 and (c) 3.50 to 1.00 for the fiscal quarter ending March 31, 2019 and each fiscal quarter thereafter; and (ii) a minimum Consolidated Fixed Charge Coverage Ratio of 1.25 to 1.00 as of the end of any fiscal quarter for the most recently completed four fiscal quarters. The Company was in compliance with all financial covenants as of December 31, 2017 . The Term Loan consists of the following (dollars in thousands): December 31, 2017 Principal balance $ 245,000 Unamortized deferred issuance costs (7,422 ) Term Loan, net 237,578 Less: current portion (10,184 ) Term Loan, non-current $ 227,394 As of December 31, 2017 , the aggregate contractual maturities of long-term borrowings for the Term Loan are as follows (dollars in thousands): Fiscal year: 2018 $ 12,250 2019 18,375 2020 24,500 2021 24,500 2022 165,375 Total $ 245,000 Interest expense recognized on the Term Loan for the year ended December 31, 2017 totaled $3.0 million for the stated interest. Amortization of debt issuance costs associated with the Term Loan was $0.5 million for the year ended December 31, 2017 , and was recorded to interest expense in the Company's Consolidated Statement of Operations. Interest expense recognized on the Revolving Credit Facility for the year ended December 31, 2017 totaled $0.1 million for the stated interest and unused commitment fee. Amortization of debt issuance costs associated with the Revolving Credit Facility was $40,000 for the year ended December 31, 2017 , and was recorded to interest expense in the Company's Consolidated Statement of Operations.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Significant components of the provision (benefit) for income taxes are as follows (in thousands): December 31, 2017 2016 2015 Current: Federal $ (615 ) $ (117 ) $ 948 State 314 246 399 Foreign 57 84 41 Total current (benefit) provision (244 ) 213 1,388 Deferred: Federal 131 (2,545 ) (4,624 ) State 238 (63 ) — Foreign 4 4 18 Total deferred benefit 373 (2,604 ) (4,606 ) Provision (benefit) for income taxes $ 129 $ (2,391 ) $ (3,218 ) The Company’s (loss) before provision (benefit) for income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2017 2016 2015 United States $ (8,198 ) $ (16,426 ) $ (9,480 ) Foreign 162 227 183 Loss before benefit for income taxes $ (8,036 ) $ (16,199 ) $ (9,297 ) Significant components of the Company’s deferred tax assets and deferred tax liabilities as of December 31, 2017 and 2016 are shown below (in thousands): December 31, 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 3,924 $ 3,255 Intangible assets 2,935 2,351 Sale-leaseback, net 628 888 Allowance for returns and discounts 5,358 4,043 Stock-based compensation 5,933 10,963 Tax credit carryforwards 5,247 3,430 Other, net 4,580 4,066 Total deferred tax assets 28,605 28,996 Valuation allowance for deferred tax assets (15,204 ) (7,774 ) Total deferred tax assets, net of valuation allowance 13,401 21,222 Deferred tax liabilities: Convertible Senior Notes (3,633 ) (7,592 ) Intangible assets (2,935 ) (7,557 ) Property, plant and equipment (7,263 ) (6,131 ) Total deferred tax liabilities (13,831 ) (21,280 ) Net deferred tax liabilities $ (430 ) $ (58 ) Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative before-tax loss incurred over the three-year periods ended December 31, 2017 and 2016 . Such objective evidence limits the ability to consider other subjective evidence such as the Company's projections for future profitability. On the basis of this evaluation, as of December 31, 2017 , the Company had recorded a valuation allowance of $15.2 million , which represents the portion of the deferred tax asset that management could no longer conclude was more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future based on changes in available evidence and additional weight may be given to subjective evidence such as the Company's projections for profitability. During the year ended December 31, 2017 , the allowance increased by $7.4 million . As of December 31, 2017 , the Company had federal net operating loss ("NOL") carryforwards of approximately $13.0 million which will begin to expire in 2018, unless previously utilized. The Company also had state NOLs of approximately $23.3 million which will begin to expire in 2026, unless previously utilized. The Company has federal research credits of $4.3 million which will begin to expire on December 31, 2031 , unless previously utilized. Additionally, the Company has federal alternative minimum tax credits of $0.6 million which have been reclassified to a tax receivable based on the new federal tax legislation. The Company has state research credits of $9.8 million , of which $9.5 million do not expire. The remaining $0.3 million begin to expire in 2028, unless previously utilized. Pursuant to Internal Revenue Code Sections 382 and 383, the Company’s use of its NOL and research credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three -year period. The provision (benefit) for income taxes reconciles to the amount computed by applying the federal statutory rate to loss before taxes as follows (in thousands): Year ended December 31, 2017 2016 2015 Tax benefit at statutory tax rate $ (2,812 ) $ (5,775 ) $ (3,254 ) State tax benefits, net of federal tax benefit (239 ) (390 ) (235 ) Permanent differences 327 129 157 Federal and state research credits—current year (484 ) (979 ) (722 ) Accrual of uncertain tax positions 142 43 101 Stock-based compensation (5,851 ) — — Impact of change in federal and state tax rate on revaluing deferred tax assets 3,357 (4 ) 56 Change in valuation allowance 5,799 4,687 756 Other (110 ) (102 ) (77 ) Provision (benefit) for income taxes $ 129 $ (2,391 ) $ (3,218 ) On December 22, 2017, the Tax Cuts and Jobs Act (the "Tax Act") was enacted into legislation, which includes a broad range of provisions affecting businesses. The Tax Act significantly revises how companies compute their U.S corporate tax liability by, among other provisions, reducing the corporate tax rate from 35% to 21% for tax years beginning after December 31, 2017, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. Pursuant to the SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act ("SAB 118"), a company may select between one of three scenarios to determine a reasonable estimate arising from the Tax Act. Those scenarios are (i) a final estimate which effectively closes the measurement window; (ii) a reasonable estimate leaving the measurement window open for future revisions; and (iii) no estimate, as the law is still being analyzed. The Company was able to provide a reasonable estimate for the revaluation of deferred taxes and the effects of the transition tax on undistributed foreign earnings and profits. As such, the Company has recorded a reduction in deferred tax assets for the revaluation of deferred taxes and a reduction of the net operating losses for the impacts of the transition tax, with both reductions offset by a decrease in the Company's full valuation allowance. As of December 31, 2017, the Company had $1.0 million of undistributed foreign earnings and profits. Pursuant to the Tax Act, the Company’s undistributed foreign earnings and profits were deemed repatriated as of December 31, 2017. As a result, the Company utilized net operating losses and generated foreign tax credits, each offset by the Company’s change in valuation allowance. Upon the distribution of foreign earnings and profits, certain foreign countries impose withholding taxes. The Company did not provide for foreign withholding taxes on the undistributed earnings and profits from certain non-U.S. subsidiaries that will be permanently reinvested outside the United States. If the foreign earnings and profits were distributed, the Company would need to accrue an additional income tax liability, potentially generating foreign tax credits for use against the Company’s U.S. tax liability, subject to certain limitations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): Year ended December 31, 2017 2016 2015 Beginning balance $ 8,604 $ 7,684 $ 7,065 Increases (decreases) related to prior year tax positions 10 (10 ) (12 ) Increases related to current year tax positions 951 773 631 Other $ — $ 157 $ — Ending balance $ 9,565 $ 8,604 $ 7,684 As of December 31, 2017 and 2016 , the unrecognized tax benefits of $9.6 million and $8.6 million , respectively, of which $8.1 million and $6.4 million , respectively, would reduce the Company’s annual effective tax rate, subject to the valuation allowance. The Company does not anticipate any significant decreases in its unrecognized tax benefits over the next 12 months. The Company's policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense. The Company has accrued approximately $0.3 million and $0.2 million of interest and penalties associated with uncertain tax positions for each of the years ended December 31, 2017 and 2016 respectively. There was no interest expense, net of accrued interest (reversed) in 2016. Interest expense, net of accrued interest (reversed) was approximately $0.1 million for both the years ended December 31, 2017 and 2015 , respectively. The Company is subject to periodic audits by domestic and foreign tax authorities; however there are no known audits at this time. Due to the carryforward of unutilized net operating loss and credit carryovers, the Company's federal tax years from 2009 and forward and state tax years 2001 and forward are subject to examination by tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock. The Company’s certificate of incorporation, as amended, authorizes the issuance of up to five million preferred shares. The Board of Directors is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. However, the amended certificate of incorporation specifies the initial series and the rights of that series. No shares of preferred stock were outstanding as of December 31, 2017 , 2016 or 2015 . Equity Incentive Plan. The Company grants stock options, time-based restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs") to employees and non-employee directors under its 2016 Equity Incentive Plan (the “2016 Plan”). The Company previously granted stock options under the Amended and Restated 2010 Equity Incentive Plan (the "2010 Plan") and the Amended and Restated 2001 Equity Incentive Plan (the "2001 Plan"). The 2010 Plan and 2001 Plan were terminated at the time of adoption of the 2016 Plan, but the terminated Plans continue to govern outstanding options granted thereunder. The Company has stock options, RSUs and PSUs outstanding, which were issued under each of these equity incentive plans to certain employees and directors. Stock options granted under these plans have terms ranging up to ten years, have exercise prices ranging from $8.50 to $41.36 per share, and generally vest over four years. As of December 31, 2017 , approximately 1.8 million shares remained available for grant under the 2016 Plan. Restricted Stock Units. The Company grants both RSUs and PSUs to certain officers, directors and management. Until the restrictions lapse, ownership of the affected restricted stock units granted to the Company’s officers, directors and management is conditional upon continuous employment with the Company. For the years ended December 31, 2017 , 2016 and 2015 , the Company granted approximately 0.3 million , 0.2 million and 0.2 million shares, respectively, of restricted stock units to officers and management, which either have a time-based four -year vesting provision or performance-based vesting provisions. For purposes of measuring compensation expense of PSUs, the amount of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The grant date of the PSUs takes place when the grant is authorized and the specific achievement goals are communicated. The recognition of compensation expense associated with the PSUs requires judgment in assessing the probability of meeting the performance goals. This may result in significant expense recognition in the period in which the performance goals are met or when achievement of the goals is deemed probable or may result in the reversal of previously recognized stock-based compensation expense if the performance criteria are deemed not probable of being met. During the year ended December 31, 2017, common stock was issued to certain members of the Board of Directors in lieu of cash compensation for these members that elected to participate and agree to hold the stock for the elected deferral period. During the years ended December 31, 2016 and 2015 , RSUs were granted to certain members of the Board of Directors in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these RSU grants were $0.1 million , $0.4 million and $0.5 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. Employee Deferred Bonus Compensation Program. For the year ended December 31, 2017 , the deferred bonus compensation program was suspended temporarily by the Board. For the years ended December 31, 2016 and 2015 , certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the cash value of their cash bonus in the form of fully vested, restricted stock units plus an additional premium as additional restricted stock units, issued under the 2016 Plan. The premium restricted stock units are subject to a one -year vesting requirement from the date of issuance. The additional premium will be determined based on the length of time of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred. Employee Stock Purchase Plan. Under the Company’s Amended and Restated 1983 Employee Stock Purchase Plan (the “ESPP”), full-time employees are allowed to purchase common stock through payroll deductions (which cannot exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six -month purchase period. As of December 31, 2017 , 1,272,274 shares had been sold under the Plan, leaving 227,726 shares available for future issuance. Share Repurchase Program. On January 25, 2016, the Company's Board of Directors authorized an amendment to extend the previously announced stock repurchase program. The Board of Directors has authorized the Company to repurchase up to an aggregate of $50.0 million in shares of our common stock under our stock repurchase program. Any shares of common stock repurchased under this program will no longer be deemed outstanding upon repurchase and will be returned to the pool of authorized shares. During the year ended December 31, 2016, 1,152,386 shares of outstanding common stock were repurchased under the Company's previously announced share repurchase program for approximately $19.6 million . During the year ended December 31, 2015, 1,397,000 shares of outstanding common stock were repurchased under the Company's previously announced share repurchase program for approximately $30.4 million . There were no repurchases during 2017 and at December 31, 2017 , $35.0 million remained available under this program. The repurchase program expired on January 25, 2018. Shares Reserved for Future Issuance. At December 31, 2017 , approximately 5.3 million shares of common stock were reserved under the Company’s equity incentive plan and 227,726 shares were reserved for purchases under the ESPP.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation For the years ended December 31, 2017 , 2016 and 2015 stock-based compensation expense was $9.1 million , $8.0 million and $7.4 million , respectively, of which $4.1 million , $4.7 million and $4.7 million , respectively, related to stock options and $4.9 million , $2.4 million and $2.0 million , respectively, related to restricted stock units. For the years ended December 31, 2017 , 2016 and 2015 , the Company recorded $0.1 million , $0.9 million and $0.7 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 5 . During the years ended December 31, 2016 and 2015 , $0.9 million and $0.6 million , respectively, was initially recorded as a component of accrued payroll and related expenses. Since the employee Deferred Bonus Compensation Program was suspended in 2017, there was no component of stock-based compensation recorded to accrued payroll related expenses as of December 31, 2017 . Stock-based compensation expense related to stock options and restricted stock units was as follows (in thousands): Year ended December 31, 2017 2016 2015 Cost of sales $ 579 $ 617 $ 581 Research and development 1,886 1,551 734 Sales and marketing 2,129 1,189 1,554 General and administrative 4,467 4,629 4,550 Total stock-based compensation expense $ 9,061 $ 7,986 $ 7,419 Stock-based compensation expense capitalized to inventory and compensation expense related to the Company’s ESPP were not material for the years ended December 31, 2017 , 2016 and 2015 . Stock Options Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. For stock options with graded vesting, the Company ensures that the cumulative amount of compensation expense recognized at the end of any reporting period at least equals the portion of the stock option that has vested at that date. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants: Year ended December 31, 2017 2016 2015 Risk-free interest rate 2.30 % 1.47 % 1.50 % Expected option life (in years) 6.63 6.59 6.24 Volatility rate 36 % 36 % 40 % Dividend rate — % — % — % The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations. The Company’s determination of fair value is affected by the Company’s stock price as well as a number of assumptions that require judgment. The weighted-average fair value per share was $8.99 , $6.00 and $9.46 for options granted during the years ended December 31, 2017 , 2016 and 2015 , respectively. The total intrinsic value was $26.8 million , $4.5 million and $1.6 million for options exercised during the years ended December 31, 2017 , 2016 and 2015 , respectively. As of December 31, 2017 , total unrecognized compensation expense related to stock options was approximately $7.7 million and the related weighted-average period over which it is expected to be recognized is approximately 1.9 years. The maximum contractual term of the Company’s stock options is ten years. A summary of the status of stock option activity for the years ended December 31, 2015 , 2016 and 2017 is as follows (in thousands, except price data and years): Number of Shares Weighted- average exercise price per share Weighted- average remaining contractual term (in years) Aggregate intrinsic value Outstanding at January 1, 2015 3,607 $ 16.37 Granted 659 23.15 Exercised (168 ) 12.30 Cancelled (131 ) 23.41 Outstanding at December 31, 2015 3,967 17.44 Granted 677 15.48 Exercised (553 ) 13.76 Cancelled (150 ) 20.86 Outstanding at December 31, 2016 3,941 17.49 Granted 263 22.21 Exercised (1,527 ) 16.38 Cancelled (18 ) 24.91 Outstanding at December 31, 2017 2,659 $ 18.54 5.69 $ 65,969 Vested and expected to vest at December 31, 2017 2,574 $ 18.51 5.61 $ 63,914 Exercisable at December 31, 2017 1,463 $ 17.71 3.99 $ 37,503 Available for future grant at December 31, 2017 1,848 Restricted Stock Units The Company grants both time-based restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs"). The fair value of RSUs and PSUs is determined based on the closing market price of the Company’s common stock on the grant date. Compensation expense for RSUs is measured at the grant date and recognized ratably over the vesting period. A portion of the restricted stock granted in 2017 is performance-based and vesting is tied to achievement of specific Company goals over a three year time period, subject to early vesting upon achievement of the performance goals. For purposes of measuring compensation expense for PSUs, the amount of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. There was no stock-based compensation expense related to PSUs for the years ended December 31, 2016 or 2015. A summary of the status of stock awards activity for the years ended December 31, 2015 , 2016 and 2017 is as follows (in thousands, except price data): Shares Weighted-average grant date fair value Non-vested at January 1, 2015 402 $ 14.84 Granted 171 22.79 Vested (96 ) 18.01 Forfeited (18 ) 22.87 Non-vested at December 31, 2015 459 21.61 Granted 185 16.14 Vested (120 ) 18.50 Forfeited (23 ) 20.80 Non-vested at December 31, 2016 501 20.37 Granted 349 22.34 Vested (100 ) 23.49 Forfeited (4 ) 18.69 Non-vested at December 31, 2017 746 $ 20.88 In 2017 , 2016 and 2015 , the Company issued approximately 0.1 million restricted stock units each year in exchange for the deferred bonus liability of $0.9 million , $0.5 million and $0.4 million , respectively. The total amount of unrecognized compensation expense related to non-vested restricted stock awards as of December 31, 2017 was approximately $13.3 million , which is expected to be recognized over a weighted-average period of approximately 1.8 years.

Earnings (Loss) Per Share (Note

Earnings (Loss) Per Share (Notes)	12 Months Ended
	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Earnings Per Share [Text Block]	Potentially dilutive shares excluded from the calculation above represent stock options when the combined exercise price and unrecognized stock-based compensation are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. Stock options, RSUs and Convertible Senior Notes that would have been included in the diluted EPS calculation if the Company had earnings amounted to 1.4 million for the year ended December 31, 2017 . Stock options and RSUs that would have been included in the diluted EPS calculation if the Company had earnings amounted to 0.8 million and 1.0 million for the years ended December 31, 2016 and 2015 , respectively. No conversion premium existed on the Convertible Senior Notes as of December 31, 2016 and 2015 ; therefore, there was no dilutive impact from the Convertible Senior Notes to diluted EPS during the years ended December 31, 2016 and 2015 .

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2017 are as follows (in thousands): Years ending December 31, Operating Leases Lease obligation 2018 $ 8,638 $ 946 2019 9,072 956 2020 9,212 967 2021 9,050 — 2022 7,412 — Thereafter 80,559 — Total minimum lease payments $ 123,943 $ 2,869 Operating Leases —Rent expense under operating leases totaled approximately $2.1 million for the year ended December 31, 2017 , $2.2 million for the year ended December 31, 2016 and $2.3 million for the year ended December 31, 2015 . In the fourth quarter of 2013 , the Company entered into a lease for approximately 30,000 square feet of office space and moved the executive and administrative functions into this facility in the second quarter of 2014. The lease expires in 2022 with options to extend the lease for two additional five -year periods. This operating lease included a lease incentive for tenant improvements of $1.7 million which has been included as a leasehold improvement in property, plant and equipment and as deferred rent in other current liabilities and non-current deferred rent. On January 5, 2018, the Company entered into a sales and leaseback transaction for the San Diego property on Summers Ridge Road that was acquired as part of the Triage Business discussed in Note 12 . As part of the transaction, the Company sold the Summers Ridge property and entered into a lease agreement with the buyer to lease two of the four buildings for a term of 15 years. The initial term can be extended for two additional five year terms upon satisfaction of certain conditions. The future minimum lease payments for this property are included in the table above. McKellar Court Lease Obligation —During 1999, the Company completed a sale and leaseback transaction of its San Diego facility at McKellar Court. The facility was sold for $15.0 million , of which $3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million . The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate . The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement for the McKellar Court property, which had no significant impact on the Company’s financial statements. The amended terms included a new ten -year lease term through December 31, 2019 , with options to extend the lease for up to three additional five -year periods. In the fourth quarter of 2015, the Company amended the terms of its lease agreement to extend the lease term through December 31, 2020. The options to extend the lease for up to three additional five -year periods commence at the new lease term date of December 31, 2020. The Company is amortizing the lease obligation over the new estimated lease term, including extensions. As the Company accounts for the lease as a financing transaction, the Company adjusted the implied interest rate so that the existing lease obligation is amortized to the end of the estimated lease term, including extensions. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership’s expected losses or receive a majority of the partnership’s residual returns. The Company made lease payments to the partnership of approximately $0.9 million , $0.9 million and $1.1 million for the years ended December 31, 2017 , 2016 and 2015 , respectively. Purchase Commitments The Company has $ 5.9 million in firm purchase commitments with respect to planned inventory and capital expenditures as of December 31, 2017 . Litigation and Other Legal Proceedings In Beckman Coulter Inc. v. Quidel Corporation, which was filed in the Superior Court for the County of San Diego, California, on November 27, 2017, Beckman Coulter (“Beckman”) alleges that a provision of an agreement between Quidel and Beckman Coulter violates state antitrust laws. Our acquisition of the BNP Business consisted of assets and liabilities relating to a contractual arrangement with Beckman (the “Beckman Agreement”) for the supply of antibodies and other inputs related to, and distribution of, the Triage® BNP Test for the Beckman Coulter Access Family of Immunoassay Systems. The Beckman Agreement further provides that Beckman, for a specified period, cannot research or develop an assay for use in the diagnosis of cardiac diseases that measures or detects the presence or absence of BNP or NT-pro-BNP (a related biomarker). In the lawsuit, Beckman asserts that this provision violates certain state antitrust laws and is unenforceable. Beckman contends that it has suffered damages due to this provision and seeks a declaration that this provision is void. We deny that the contractual provision is unlawful, deny any liability with respect to this matter, and intend to vigorously defend ourselves. There are multiple factors that prevent us from being able to estimate the amount of loss, if any, that may result from this matter including: (1) we are vigorously defending ourselves and believe that we have a number of meritorious legal defenses; (2) there are unresolved questions of law and fact that could be important to the ultimate resolution of this matter; and (3) discovery is in the very early stages. Accordingly, at this time, we are not able to estimate a possible loss or range of loss that may result from this matter or to determine whether such loss, if any, would have a material adverse effect on our financial condition, results of operations or liquidity. From time to time, the Company is involved in other litigation and proceedings, including matters related to product liability claims, commercial disputes and intellectual property claims, as well as regulatory, employment, and other claims related to our business. The Company accrues for legal claims when, and to the extent that, amounts associated with the claims become probable and are reasonably estimable. The actual costs of resolving legal claims may be substantially higher or lower than the amounts accrued for those claims. For those matters as to which we are not able to estimate a possible loss or range of loss, we are not able to determine whether the loss will have a material adverse effect on our business, financial condition or results of operations or liquidity. No accrual has been recorded as of December 31, 2017 and December 31, 2016 related to such matters as they are not probable and/or reasonably estimable. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. However, the resolution of, or increase in any accruals for, one or more matters may have a material adverse effect on the Company's results of operations and cash flows. The Company also maintains insurance, including coverage for product liability claims, in amounts which management believes are appropriate given the nature of its business. Licensing Arrangements The Company has entered into various licensing and royalty agreements, which largely require payments by the Company based on specified product sales as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $0.6 million , $0.8 million and $0.5 million for the years ended December 31, 2017 , 2016 and 2015 , respectively.

Industry and Geographic Informa

Industry and Geographic Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Industry and Geographic Information	The Company operates in one reportable segment. Sales to customers outside the U.S. represented 18% , 17% and 14% of total revenue for the years ended December 31, 2017 , 2016 and 2015 , respectively. As of December 31, 2017 and 2016 , balances due from foreign customers, in U.S. dollars, were $18.8 million and $6.8 million , respectively. The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2017 2016 2015 Customer: A 21 % 16 % 20 % B 20 % 15 % 17 % C 13 % 13 % 11 % 54 % 44 % 48 % As of December 31, 2017 and 2016 , accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $44.4 million and $13.9 million , respectively. The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue for the years ended December 31, 2017 2016 2017 2016 2015 Domestic $ 59,833 $ 50,774 $ 227,611 $ 158,244 $ 168,809 Foreign 1,752 84 50,132 33,359 27,320 Total $ 61,585 $ 50,858 $ 277,743 $ 191,603 $ 196,129 Consolidated net revenues by product category are as follows (in thousands): Year ended December 31, 2017 2016 2015 Rapid Immunoassay $ 165,099 $ 121,416 $ 130,348 Cardiac Immunoassay 47,030 — — Specialized Diagnostic Solutions 51,978 60,681 60,358 Molecular Diagnostic Solutions 13,636 9,506 5,423 Total revenues $ 277,743 $ 191,603 $ 196,129

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2017 December 31, 2016 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents 36,086 — — 36,086 133,540 — — 133,540 Total assets at fair value $ 36,086 $ — $ — $ 36,086 $ 133,540 $ — $ — $ 133,540 Liabilities: Contingent consideration — — 24,301 24,301 — — 5,175 5,175 Deferred consideration — 223,158 — 223,158 — — — — Total liabilities at fair value $ — $ 223,158 $ 24,301 $ 247,459 $ — $ — $ 5,175 $ 5,175 There were no transfers of assets or liabilities between Level 1, Level 2 and Level 3 categories of the fair value hierarchy during the years ended December 31, 2017 and 2016 . The Company used Level 1 inputs to determine the fair value of its cash equivalents, which primarily consist of funds held in government money market accounts and commercial paper. As such, the carrying value of cash equivalents approximates fair value. As of December 31, 2017 and 2016 , the carrying value of cash equivalents was $36.1 million and $133.5 million , respectively. In connection with the acquisition of the BNP Business, the Company will pay up to $280.0 million in cash, of which $256.0 million is guaranteed and is considered deferred consideration and $24.0 million is contingent consideration. The fair value of the deferred consideration was determined to be $220.6 million on the acquisition date based on the net present value of cash payments using an estimated borrowing rate using a quoted price for a similar liability. The Company recorded 2.6 million for the accretion of interest on the deferred consideration in the fourth quarter of 2017. The fair value of contingent consideration on the acquisition date was $19.7 million and was calculated using a discounted probability weighted valuation model. In conjunction with the acquisitions of BioHelix Corporation in May 2013, AnDiaTec GmbH & Co. KG in August 2013 and Immutopics, Inc. in March 2016, the Company recorded contingent consideration of $4.6 million as of December 31, 2017 and $5.2 million as of December 31, 2016 . The Company assesses the fair value of contingent consideration to be settled in cash related to these prior acquisitions using a discounted revenue model. Significant assumptions used in the measurement include revenue projections and discount rates. This fair value measurement of contingent consideration is based on significant inputs not observed in the market and thus represent Level 3 measurements. Due to changes in the estimated payments and a shorter discounting period related to the various contingent consideration liabilities, the fair value of the contingent consideration changed during the years ended 2017 , 2016 and 2015 . These changes resulted in gains of $0.1 million , $0.5 million and $0.1 million recorded to cost of sales in the Consolidated Statements of Operations during the years ended December 31, 2017 , 2016 and 2015, respectively. Changes in estimated fair value of contingent consideration liabilities from December 31, 2016 through December 31, 2017 are as follows (in thousands): Contingent consideration liability (Level 3 measurement) Balance at December 31, 2016 $ 5,175 Cash payments (498 ) Net gain recorded for fair value adjustments (80 ) Additional liability recorded for the BNP Business 19,700 Unrealized loss on foreign currency translation 4 Balance at December 31, 2017 $ 24,301

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Employee Benefit Plan	Employee Benefit Plan The Company has a defined contribution 401(k) plan (the “401(k) Plan”) covering all employees who are eligible to join the 401(k) Plan upon employment. Employee contributions are subject to a maximum limit by federal law. This Plan includes an employer match of 50% on the first 6% of pay contributed by the employee. The Company contributed approximately $1.5 million , $1.5 million and $1.3 million to the 401(k) Plan during the years ended December 31, 2017 , 2016 and 2015 , respectively.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisition	On October 6, 2017, the Company acquired the Triage and BNP Businesses. The acquisition has been accounted for in conformity with ASC Topic 805, Business Combinations . In connection with the acquisition of the Triage Business, the Company paid $399.8 million in cash and assumed certain liabilities. These acquisitions enhance the Company's revenue profile and expand the Company's geographic footprint and product diversity. The Company used proceeds from the Term Loan (defined and discussed in Note 3 ) of $245.0 million and cash on hand to pay (i) the consideration for the Triage Business and (ii) fees and expenses incurred in connection with the acquisition of the Triage and BNP Businesses. In connection with the acquisition of the BNP Business, the Company: (i) will pay (A) $16.0 million in cash plus up to an additional $24.0 million in contingent consideration, payable in five annual installments of up to $8.0 million , the first of which will be paid on April 30, 2018, (B) $240.0 million in cash, payable in six annual installments of $40.0 million each, the first of which will be paid on April 30, 2018 and (C) $0.2 million in cash for certain inventory related adjustments; and (ii) assumed certain liabilities. The purchase price consideration is as follows (in thousands): Cash consideration—Triage Business $ 399,798 Deferred consideration—BNP Business 220,550 Contingent consideration—BNP Business 19,700 Inventory related adjustment 205 Net consideration $ 640,253 The fair value of the deferred consideration was determined to be $220.6 million on the acquisition date based on the net present value of cash payments using an estimated borrowing rate using a quoted price for a similar liability. The fair value of contingent consideration on the acquisition date was $19.7 million and was calculated using a discounted probability weighted valuation model. The Company is still finalizing the allocation of the purchase price, therefore, the purchase price allocation or the provisional measurements of intangible assets, goodwill and deferred income tax assets or liabilities may be adjusted if the Company recognizes additional assets or liabilities to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. The Company expects to complete the allocation of purchase price during fiscal year 2018. The components of the preliminary purchase price allocation at the acquisition date and the purchase price consideration transferred at December 31, 2017 are as follows: Prepaid expenses and other current assets $ 796 Assets held for sale 146,540 Inventories 52,205 Property, plant and equipment 10,608 Intangible assets 184,900 Goodwill 245,531 Other non-current assets 182 Total assets acquired $ 640,762 Other current liabilities (509 ) Total net assets and liabilities acquired $ 640,253 Goodwill represents the excess of the total purchase price over the fair value of the underlying net assets, largely arising from synergies expected to be achieved by the combined Company and the expanded revenue profile and product diversity. The goodwill is expected to be fully deductible for tax purposes. The following sets forth results of the amounts assigned to the identifiable intangible assets acquired (in thousands): Intangible Asset Amortization period Fair value of assets acquired Purchased technology 10 years $ 52,400 Customer relationships 7 years 115,000 Trademarks 10 years 17,500 Total intangible assets $ 184,900 The fair value of the identified intangible assets was determined primarily using an income based approach. Intangible assets are amortized on a straight-line basis over the amortization periods noted above. The following unaudited pro forma financial information shows the combined results of operations of the Company, including the Triage and BNP Businesses, as if the acquisition had occurred as of the beginning of the periods presented: Year ended December 31, (in thousands, except per share data) 2017 2016 Pro forma total revenues $ 468,577 $ 437,525 Pro forma net income (1) $ 41,296 $ 28,045 Pro forma basic earnings per share $ 1.22 $ 0.86 Pro forma diluted net earnings per share $ 1.18 $ 0.84 Total revenue included in the Consolidated Statement of Operations since acquisition $ 47,030 Net loss included in the Consolidated Statement of Operations since acquisition (2) $ (4,776 ) (1) Includes the reversal of non-recurring transaction costs totaling $11.7 million directly attributable to the acquisition incurred during the year ended December 31, 2017. Pro forma net income also includes the reversal of the amortization of the fair value step-up of inventory of $11.0 million because it does not have a continuing impact. (2) Net loss of $4.8 million includes amortization of the fair value write-up of inventory of $11.0 million , amortization of acquired intangible assets of $5.9 million , cash and non-cash interest expense on the Term Loan of $3.5 million and accretion of interest on the deferred consideration of $2.6 million .

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited) First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2017 Total revenues $ 73,692 $ 38,267 $ 50,894 $ 114,890 Gross profit (1) $ 48,499 $ 18,826 $ 29,690 $ 59,127 Operating income (loss) $ 19,229 $ (11,027 ) $ (2,537 ) $ 3,887 Net income (loss) $ 14,290 $ (11,842 ) $ (5,525 ) $ (5,088 ) Basic income (loss) per share $ 0.43 $ (0.35 ) $ (0.16 ) $ (0.15 ) Diluted income (loss) per share $ 0.42 $ (0.35 ) $ (0.16 ) $ (0.15 ) 2016 Total revenues $ 50,321 $ 39,133 $ 49,341 $ 52,808 Gross profit (1) $ 29,482 $ 20,225 $ 30,023 $ 32,001 Operating income (2) $ (3,460 ) $ (9,019 ) $ 2,125 $ 5,915 Net loss $ (3,446 ) $ (7,840 ) $ (572 ) $ (1,950 ) Basic and diluted loss per share (3) $ (0.11 ) $ (0.24 ) $ (0.02 ) $ (0.06 ) (1) Includes reclassification of $1.6 million , $1.7 million and $1.8 million from amortization of intangible assets from acquired business and technology to cost of sales expense for the first, second and third quarters, respectively, in the year ended December 31, 2017. Includes reclassification of $1.6 million , $1.6 million , $1.6 million and $1.7 million from amortization of intangible assets from acquired business and technology to cost of sales expense for the first, second, third and fourth quarters in the year ended December 31, 2016, respectively. (2) Includes reclassification of $0.7 million from amortization of intangible assets from acquired business and technology to sales and marketing expense for each of the first, second and third quarters in the year ended December 31, 2017. Includes reclassification of $0.6 million , $0.7 million , $0.7 million and $0.6 million from amortization of intangible assets from acquired business and technology to sales and marketing expense for the first, second, third and fourth quarters, respectively, in the year ended December 31, 2016. (3) Basic and diluted EPS amounts in each quarter are computed using the weighted-average number of shares outstanding during that quarter, while basic and diluted EPS for the full year is computed using the weighted-average number of shares outstanding during the year. Therefore, the sum of the four quarters’ basic or diluted EPS may not equal the full year basic or diluted EPS.

Consolidated Valuation and Qual

Consolidated Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2017
Valuation and Qualifying Accounts [Abstract]
Consolidated Valuation and Qualifying Accounts	SCHEDULE II QUIDEL CORPORATION CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS Description Balance at beginning of period Additions charged to expense or as reductions to revenue (1) Deductions (2) Balance at end of period (in thousands) Year ended December 31, 2017 Accounts receivable allowance $ 7,165 $ 36,449 $ (31,305 ) $ 12,309 Year ended December 31, 2016: Accounts receivable allowance $ 7,488 $ 28,329 $ (28,652 ) $ 7,165 Year ended December 31, 2015: Accounts receivable allowance $ 8,221 $ 31,532 $ (32,265 ) $ 7,488 (1) Represents charges associated primarily to accruals for early payment discounts, volume discounts and contract rebates recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to sales and marketing expenses. (2) The deductions represent actual charges against the accrual described above.

Subsequent Events (Notes)

Subsequent Events (Notes)	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events On January 5, 2018, the Company entered into a sale and leaseback transaction for the San Diego property on Summers Ridge Road that was acquired as part of the Triage Business from Alere discussed in Note 12 and is included as assets held for sale on the Consolidated Balance Sheet as of the year ended December 31, 2017. The Company sold the Summers Ridge property for net consideration of $146.6 million . In addition, the Company entered into a lease agreement with the buyer to lease two of the four buildings on the Summers Ridge campus for a term of 15 years. On January 11, 2018, the Company used $100.0 million of net cash proceeds from the sale and leaseback transaction to pay down a portion of the existing Term Loan under its Credit Agreement described in Note 3 . Following the payment, the Company has approximately $145.0 million remaining in Term Loan outstanding. Separately, the Company also repaid the entire outstanding $10.0 million balance on its Revolving Credit Facility under the Credit Agreement.

Company Operations and Summar23

Company Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Consolidation	Consolidation— The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. The Company invests its cash equivalents primarily in money market funds and commercial paper. Cash equivalents are maintained with high quality institutions.
Accounts Receivable	Accounts Receivable— The Company sells its products directly to hospitals and reference laboratories as well as to distributors in the U.S. and sells directly to hospitals and labs and through distribution internationally (see Note 9 ). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company’s reserves primarily consist of amounts related to cash discounts and contract rebates. The balance of accounts receivable is net of reserves of $12.3 million and $7.2 million at December 31, 2017 and 2016 , respectively.
Concentration of Credit Risk	Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consists principally of trade accounts receivable. The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored regularly by reviewing credit history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventories	Inventories— Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. The Company reviews the components of its inventory on a quarterly basis for excess, obsolete and impaired inventory and makes appropriate dispositions as obsolete stock is identified.
Property, Plant and Equipment	Property, Plant and Equipment— Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets ( three to 15 years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the estimated useful lives of the assets.
Intangible Assets	Goodwill and Intangible Assets— Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for indefinite-lived intangibles such as goodwill. Software development costs associated with software to be leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized. The capitalized cost is amortized on a straight-line basis over the estimated product life or on the ratio of current revenues to total projected product revenues, whichever is greater.
Impairment of Long-Lived Assets
Convertible Debt	Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 3 for additional discussion of the Convertible Senior Notes issued in December 2014.
Revenue Recognition	Revenue Recognition—
Research and Development Costs	Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred.
Product Shipment Costs	Product Shipment Costs— Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Operations.
Advertising Costs	Advertising Costs— Advertising costs are expensed as incurred.
Deferred Rent	Deferred Rent— The Company enters into lease arrangements for office space under non-cancelable operating leases. Certain of the operating lease agreements contain rent escalation provisions, which are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the leased property for purposes of recognizing lease expense on a straight-line basis over the term of the lease. The Company does not assume renewals in the determination of the lease term unless the renewals are deemed to be reasonably assured at lease inception. The difference between rent expense and amounts paid under the Company's lease agreements are recorded as deferred rent.
Income Taxes	Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —
Product Warranty	Product Warranty —The Company generally sells products with a limited product warranty and certain limited indemnifications. Due to product testing, the short time between product shipment and the detection and correction of product failures and a low historical rate of payments on indemnification claims, the historical activity and the related expense were not significant for the fiscal years presented.
Stock-Based Compensation	Stock-Based Compensation —Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. The fair value of restricted stock units is determined based on the closing market price of the Company’s common stock on the grant date.
Earnings Per Share	Computation of (Loss) Earnings Per Share —For the years ended December 31, 2017 , 2016 and 2015 , basic loss per share was computed by dividing net loss by the weighted-average number of common shares outstanding, including restricted stock units vested during the period. Diluted earnings per share (“EPS”) reflects the potential dilution that could occur if the earnings were divided by the weighted-average number of common shares and potentially dilutive common shares from outstanding stock options, unvested restricted stock units and the 3.25% Convertible Senior Notes due 2020 (“Convertible Senior Notes”). Potentially dilutive common shares from outstanding stock options and unvested restricted stock units are determined using the average share price for each period under the treasury stock method.
Comprehensive (Loss) Income	Comprehensive Loss —Comprehensive loss includes unrealized gains and losses which are related to the cumulative translation adjustments excluded from the Company’s Consolidated Statements of Operations.
Use of Estimates	Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Periods	Accounting Periods —Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ends are December 31, 2017, January 1, 2017 and January 3, 2016. For ease of reference, the calendar quarter end dates are used herein.
Recent Accounting Pronouncements	Recent Accounting Pronouncements —In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance codified in Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition ("ASC 605"). The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current authoritative guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The FASB has issued several amendments to the new standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations. ASU 2014-09 and all subsequent amendments (collectively, the “ASC 606”) will be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. The Company will adopt ASC 606 on January 1, 2018, using the modified retrospective transition method applied to those contracts which were not completed as of that date. Our evaluation of our contracts subject to this standard is substantially complete and based on procedures completed to date, we do not expect the application of the new standard to these contracts to have a material impact to our Consolidated Statements of Operations or Balance Sheets at initial implementation. We are also evaluating the new disclosures required by the standard to determine what additional information will need to be disclosed. In February 2016, the FASB issued guidance codified in ASU 2016-02 (Topic 842), Leases . The guidance requires a lessee to recognize a lease liability for the obligation to make lease payments and a right-to-use asset representing the right to use the underlying asset for the lease term on the balance sheet. The guidance is effective for fiscal years beginning after December 15, 2018 including interim periods within those years. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2019. In January 2017, the FASB issued guidance codified in ASU 2017-04, Intangibles-Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). Under this new guidance, an entity will no longer determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Instead, an entity will compare the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. The guidance is effective for fiscal years beginning after December 15, 2019 including interim periods therein. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2020. In March 2016, the FASB issued guidance codified in ASU 2016-09 (Topic 718), Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”) . This guidance includes provisions to simplify several aspects of accounting for share-based payment transactions, including income tax consequences, accounting for forfeitures, classification of awards as either equity or liability and classification on the statement of cash flows. ASU 2016-09 includes a requirement that the tax effect related to the settlement of share-based awards be recorded within income tax expense or benefit in the income statement. The simplification of income tax accounting for share-based payment transactions also impacts the computation of weighted-average diluted shares outstanding under the treasury stock method. The Company adopted ASU 2016-09 in the first quarter of 2017 and the impact of the adoption resulted in the following: • Upon adoption, the balance of the unrecognized excess tax benefits of $1.8 million was recorded as an increase to deferred tax assets and a corresponding increase to the valuation allowance, resulting in no impact to retained earnings. • Excess tax benefits from share-based arrangements are to be classified within cash flow from operating activities, rather than as cash flow from financing activities. The Company applied this provision on a retrospective basis and the prior period statement of cash flows was adjusted. This adoption did not have a material impact on the Company’s cash flows. • The Company elected to continue to estimate the number of awards expected to be forfeited and adjust the estimate when appropriate, as is currently required. This adoption did not have a material impact on the Company’s consolidated results of operations, financial condition or cash flows. • There was no material impact on the computation of weighted-average diluted shares outstanding.

Balance Sheet Account Details24

Balance Sheet Account Details (Tables)	12 Months Ended
	Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]
Summary of Inventories	December 31, 2017 2016 Raw materials $ 22,252 $ 9,297 Work-in-process (materials, labor and overhead) 22,813 7,990 Finished goods (materials, labor and overhead) 22,013 8,758 Total inventories $ 67,078 $ 26,045
Property, Plant and Equipment	The following is a summary of property, plant and equipment (in thousands): December 31, 2017 2016 Equipment, furniture and fixtures $ 75,728 $ 61,972 Building and improvements 34,994 34,243 Leased instruments 32,458 24,014 Land 1,080 1,080 Total property, plant and equipment, gross 144,260 121,309 Less: accumulated depreciation and amortization (82,675 ) (70,451 ) Total property, plant and equipment, net $ 61,585 $ 50,858
Summary of Intangible Assets
Summary of Expected Future Annual Amortization Expense	The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands): For the years ending December 31, Amortization expense 2018 $ 28,799 2019 27,542 2020 27,144 2021 26,996 2022 26,472 Thereafter 66,874 Total $ 203,827
Schedule of Other Current Liabilities	The following is a summary of other current liabilities (in thousands): December 31, 2017 2016 Customer incentives $ 7,165 $ 3,766 Accrued interest 442 227 Other 5,059 1,104 Total other current liabilities $ 12,666 $ 5,097

Debt Tables (Tables)

Debt Tables (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	As of December 31, 2017 , the aggregate contractual maturities of long-term borrowings for the Term Loan are as follows (dollars in thousands): Fiscal year: 2018 $ 12,250 2019 18,375 2020 24,500 2021 24,500 2022 165,375 Total $ 245,000
Schedule of Long-term Debt Instruments	The following table summarizes information about the equity and liability components of the Convertible Senior Notes (dollars in thousands). The fair values of the respective notes outstanding were measured based on quoted market prices: December 31, 2017 2016 Principal amount of Convertible Senior Notes outstanding $ 167,314 $ 167,314 Unamortized discount of liability component (15,356 ) (20,221 ) Unamortized deferred issuance costs (2,090 ) (2,753 ) Net carrying amount of liability component 149,868 144,340 Less: current portion — — Long-term debt $ 149,868 $ 144,340 Carrying value of equity component, net of issuance costs $ 29,211 $ 29,211 Fair value of outstanding Convertible Senior Notes $ 257,245 $ 165,223 Remaining amortization period of discount on the liability component 3 years 4 years

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Components of (Benefit) Provision for Income Taxes	Significant components of the provision (benefit) for income taxes are as follows (in thousands): December 31, 2017 2016 2015 Current: Federal $ (615 ) $ (117 ) $ 948 State 314 246 399 Foreign 57 84 41 Total current (benefit) provision (244 ) 213 1,388 Deferred: Federal 131 (2,545 ) (4,624 ) State 238 (63 ) — Foreign 4 4 18 Total deferred benefit 373 (2,604 ) (4,606 ) Provision (benefit) for income taxes $ 129 $ (2,391 ) $ (3,218 )
Schedule of Income before (Benefit) Provision for Income Taxes	The Company’s (loss) before provision (benefit) for income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2017 2016 2015 United States $ (8,198 ) $ (16,426 ) $ (9,480 ) Foreign 162 227 183 Loss before benefit for income taxes $ (8,036 ) $ (16,199 ) $ (9,297 )
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and deferred tax liabilities as of December 31, 2017 and 2016 are shown below (in thousands): December 31, 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 3,924 $ 3,255 Intangible assets 2,935 2,351 Sale-leaseback, net 628 888 Allowance for returns and discounts 5,358 4,043 Stock-based compensation 5,933 10,963 Tax credit carryforwards 5,247 3,430 Other, net 4,580 4,066 Total deferred tax assets 28,605 28,996 Valuation allowance for deferred tax assets (15,204 ) (7,774 ) Total deferred tax assets, net of valuation allowance 13,401 21,222 Deferred tax liabilities: Convertible Senior Notes (3,633 ) (7,592 ) Intangible assets (2,935 ) (7,557 ) Property, plant and equipment (7,263 ) (6,131 ) Total deferred tax liabilities (13,831 ) (21,280 ) Net deferred tax liabilities $ (430 ) $ (58 )
Reconciliation of Income Tax Computed at Federal Statutory Rate	Year ended December 31, 2017 2016 2015 Tax benefit at statutory tax rate $ (2,812 ) $ (5,775 ) $ (3,254 ) State tax benefits, net of federal tax benefit (239 ) (390 ) (235 ) Permanent differences 327 129 157 Federal and state research credits—current year (484 ) (979 ) (722 ) Accrual of uncertain tax positions 142 43 101 Stock-based compensation (5,851 ) — — Impact of change in federal and state tax rate on revaluing deferred tax assets 3,357 (4 ) 56 Change in valuation allowance 5,799 4,687 756 Other (110 ) (102 ) (77 ) Provision (benefit) for income taxes $ 129 $ (2,391 ) $ (3,218 )
Summary of Unrecognized Tax Benefits	The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): Year ended December 31, 2017 2016 2015 Beginning balance $ 8,604 $ 7,684 $ 7,065 Increases (decreases) related to prior year tax positions 10 (10 ) (12 ) Increases related to current year tax positions 951 773 631 Other $ — $ 157 $ — Ending balance $ 9,565 $ 8,604 $ 7,684

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation Expense Related to Stock-Based Compensation Plans	tock-based compensation expense related to stock options and restricted stock units was as follows (in thousands): Year ended December 31, 2017 2016 2015 Cost of sales $ 579 $ 617 $ 581 Research and development 1,886 1,551 734 Sales and marketing 2,129 1,189 1,554 General and administrative 4,467 4,629 4,550 Total stock-based compensation expense $ 9,061 $ 7,986 $ 7,419
Estimated Fair Value of Each Stock Option Award	The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants: Year ended December 31, 2017 2016 2015 Risk-free interest rate 2.30 % 1.47 % 1.50 % Expected option life (in years) 6.63 6.59 6.24 Volatility rate 36 % 36 % 40 % Dividend rate — % — % — %
Summary of Status of Stock Option Activity	A summary of the status of stock option activity for the years ended December 31, 2015 , 2016 and 2017 is as follows (in thousands, except price data and years): Number of Shares Weighted- average exercise price per share Weighted- average remaining contractual term (in years) Aggregate intrinsic value Outstanding at January 1, 2015 3,607 $ 16.37 Granted 659 23.15 Exercised (168 ) 12.30 Cancelled (131 ) 23.41 Outstanding at December 31, 2015 3,967 17.44 Granted 677 15.48 Exercised (553 ) 13.76 Cancelled (150 ) 20.86 Outstanding at December 31, 2016 3,941 17.49 Granted 263 22.21 Exercised (1,527 ) 16.38 Cancelled (18 ) 24.91 Outstanding at December 31, 2017 2,659 $ 18.54 5.69 $ 65,969 Vested and expected to vest at December 31, 2017 2,574 $ 18.51 5.61 $ 63,914 Exercisable at December 31, 2017 1,463 $ 17.71 3.99 $ 37,503 Available for future grant at December 31, 2017 1,848
Summary of Status of Stock Awards Activity	A summary of the status of stock awards activity for the years ended December 31, 2015 , 2016 and 2017 is as follows (in thousands, except price data): Shares Weighted-average grant date fair value Non-vested at January 1, 2015 402 $ 14.84 Granted 171 22.79 Vested (96 ) 18.01 Forfeited (18 ) 22.87 Non-vested at December 31, 2015 459 21.61 Granted 185 16.14 Vested (120 ) 18.50 Forfeited (23 ) 20.80 Non-vested at December 31, 2016 501 20.37 Granted 349 22.34 Vested (100 ) 23.49 Forfeited (4 ) 18.69 Non-vested at December 31, 2017 746 $ 20.88

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Twelve months ended December 31, 2017 2016 2015 Shares used in basic loss per share (weighted-average common shares outstanding) 33,734 32,708 34,104 Effect of potentially dilutive shares issuable from stock options, RSUs and Convertible Senior Notes — — — Shares used in diluted loss per share calculation 33,734 32,708 34,104 Potentially dilutive shares excluded from calculation due to anti-dilutive effect 37 2,770 1,902

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments for Minimum Rentals under Non-cancelable Leases	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2017 are as follows (in thousands): Years ending December 31, Operating Leases Lease obligation 2018 $ 8,638 $ 946 2019 9,072 956 2020 9,212 967 2021 9,050 — 2022 7,412 — Thereafter 80,559 — Total minimum lease payments $ 123,943 $ 2,869

Industry and Geographic Infor30

Industry and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Sales to Individual Customers in Excess of 10% of Total Revenue	The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2017 2016 2015 Customer: A 21 % 16 % 20 % B 20 % 15 % 17 % C 13 % 13 % 11 % 54 % 44 % 48 %
Long-Lived Assets (Excluding Intangible Assets) and Total Net Revenue	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue for the years ended December 31, 2017 2016 2017 2016 2015 Domestic $ 59,833 $ 50,774 $ 227,611 $ 158,244 $ 168,809 Foreign 1,752 84 50,132 33,359 27,320 Total $ 61,585 $ 50,858 $ 277,743 $ 191,603 $ 196,129
Consolidated Net Product Revenues by Disease State	Consolidated net revenues by product category are as follows (in thousands): Year ended December 31, 2017 2016 2015 Rapid Immunoassay $ 165,099 $ 121,416 $ 130,348 Cardiac Immunoassay 47,030 — — Specialized Diagnostic Solutions 51,978 60,681 60,358 Molecular Diagnostic Solutions 13,636 9,506 5,423 Total revenues $ 277,743 $ 191,603 $ 196,129

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2017 December 31, 2016 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents 36,086 — — 36,086 133,540 — — 133,540 Total assets at fair value $ 36,086 $ — $ — $ 36,086 $ 133,540 $ — $ — $ 133,540 Liabilities: Contingent consideration — — 24,301 24,301 — — 5,175 5,175 Deferred consideration — 223,158 — 223,158 — — — — Total liabilities at fair value $ — $ 223,158 $ 24,301 $ 247,459 $ — $ — $ 5,175 $ 5,175
Changes in Estimated Fair Value of Contingent Consideration Liabilities	Changes in estimated fair value of contingent consideration liabilities from December 31, 2016 through December 31, 2017 are as follows (in thousands): Contingent consideration liability (Level 3 measurement) Balance at December 31, 2016 $ 5,175 Cash payments (498 ) Net gain recorded for fair value adjustments (80 ) Additional liability recorded for the BNP Business 19,700 Unrealized loss on foreign currency translation 4 Balance at December 31, 2017 $ 24,301

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Business Acquisition	The purchase price consideration is as follows (in thousands): Cash consideration—Triage Business $ 399,798 Deferred consideration—BNP Business 220,550 Contingent consideration—BNP Business 19,700 Inventory related adjustment 205 Net consideration $ 640,253
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Prepaid expenses and other current assets $ 796 Assets held for sale 146,540 Inventories 52,205 Property, plant and equipment 10,608 Intangible assets 184,900 Goodwill 245,531 Other non-current assets 182 Total assets acquired $ 640,762 Other current liabilities (509 ) Total net assets and liabilities acquired $ 640,253
Finite-Lived Intangible Assets Acquired as Part of Business Combination	The following sets forth results of the amounts assigned to the identifiable intangible assets acquired (in thousands): Intangible Asset Amortization period Fair value of assets acquired Purchased technology 10 years $ 52,400 Customer relationships 7 years 115,000 Trademarks 10 years 17,500 Total intangible assets $ 184,900
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information shows the combined results of operations of the Company, including the Triage and BNP Businesses, as if the acquisition had occurred as of the beginning of the periods presented: Year ended December 31, (in thousands, except per share data) 2017 2016 Pro forma total revenues $ 468,577 $ 437,525 Pro forma net income (1) $ 41,296 $ 28,045 Pro forma basic earnings per share $ 1.22 $ 0.86 Pro forma diluted net earnings per share $ 1.18 $ 0.84 Total revenue included in the Consolidated Statement of Operations since acquisition $ 47,030 Net loss included in the Consolidated Statement of Operations since acquisition (2) $ (4,776 ) (1) Includes the reversal of non-recurring transaction costs totaling $11.7 million directly attributable to the acquisition incurred during the year ended December 31, 2017. Pro forma net income also includes the reversal of the amortization of the fair value step-up of inventory of $11.0 million because it does not have a continuing impact. (2) Net loss of $4.8 million includes amortization of the fair value write-up of inventory

Selected Quarterly Financial 33

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2017 Total revenues $ 73,692 $ 38,267 $ 50,894 $ 114,890 Gross profit (1) $ 48,499 $ 18,826 $ 29,690 $ 59,127 Operating income (loss) $ 19,229 $ (11,027 ) $ (2,537 ) $ 3,887 Net income (loss) $ 14,290 $ (11,842 ) $ (5,525 ) $ (5,088 ) Basic income (loss) per share $ 0.43 $ (0.35 ) $ (0.16 ) $ (0.15 ) Diluted income (loss) per share $ 0.42 $ (0.35 ) $ (0.16 ) $ (0.15 ) 2016 Total revenues $ 50,321 $ 39,133 $ 49,341 $ 52,808 Gross profit (1) $ 29,482 $ 20,225 $ 30,023 $ 32,001 Operating income (2) $ (3,460 ) $ (9,019 ) $ 2,125 $ 5,915 Net loss $ (3,446 ) $ (7,840 ) $ (572 ) $ (1,950 ) Basic and diluted loss per share (3) $ (0.11 ) $ (0.24 ) $ (0.02 ) $ (0.06 ) First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2017 Total revenues $ 73,692 $ 38,267 $ 50,894 $ 114,890 Gross profit (1) $ 48,499 $ 18,826 $ 29,690 $ 59,127 Operating income (loss) $ 19,229 $ (11,027 ) $ (2,537 ) $ 3,887 Net income (loss) $ 14,290 $ (11,842 ) $ (5,525 ) $ (5,088 ) Basic income (loss) per share $ 0.43 $ (0.35 ) $ (0.16 ) $ (0.15 ) Diluted income (loss) per share $ 0.42 $ (0.35 ) $ (0.16 ) $ (0.15 ) 2016 Total revenues $ 50,321 $ 39,133 $ 49,341 $ 52,808 Gross profit (1) $ 29,482 $ 20,225 $ 30,023 $ 32,001 Operating income (2) $ (3,460 ) $ (9,019 ) $ 2,125 $ 5,915 Net loss $ (3,446 ) $ (7,840 ) $ (572 ) $ (1,950 ) Basic and diluted loss per share (3) $ (0.11 ) $ (0.24 ) $ (0.02 ) $ (0.06 ) (1) Includes reclassification of $1.6 million , $1.7 million and $1.8 million from amortization of intangible assets from acquired business and technology to cost of sales expense for the first, second and third quarters, respectively, in the year ended December 31, 2017. Includes reclassification of $1.6 million , $1.6 million , $1.6 million and $1.7 million from amortization of intangible assets from acquired business and technology to cost of sales expense for the first, second, third and fourth quarters in the year ended December 31, 2016, respectively. (2) Includes reclassification of $0.7 million from amortization of intangible assets from acquired business and technology to sales and marketing expense for each of the first, second and third quarters in the year ended December 31, 2017. Includes reclassification of $0.6 million , $0.7 million , $0.7 million and $0.6 million from amortization of intangible assets from acquired business and technology to sales and marketing expense for the first, second, third and fourth quarters, respectively, in the year ended December 31, 2016. (3) Basic and diluted EPS amounts in each quarter are computed using the weighted-average number of shares outstanding during that quarter, while basic and diluted EPS for the full year is computed using the weighted-average number of shares outstanding during the year. Therefore, the sum of the four quarters’ basic or diluted EPS may not equal the full year basic or diluted EPS.

Company Operations and Summar34

Company Operations and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	1 Months Ended	3 Months Ended					12 Months Ended					50 Months Ended
	Jul. 31, 2016USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2017USD ($)Segment	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2016USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Valuation Allowances and Reserves, Balance							$ 1.8	$ 1.8
Number of business segment | Segment								1
Cash and cash equivalents maximum maturity period								3 months
Product shipment costs						$ 3.9		$ 3.7	$ 3.8
Account receivable, reserves			$ 7.2				12.3	12.3	7.2			$ 7.2
Advertising cost expensed						0.7		0.5	0.3
Company's grant revenue		$ 0						$ 6.5	5.1			20.9
Prior period reclassification adjustment	$ 0.6		$ 6.5	$ 0.7	$ 0.7	$ 2.5	$ 2.6		$ 0.7	$ 6.3	$ 2.4	$ 0.6
Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of the assets								3 years
Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of the assets								15 years

Balance Sheet Account Details

Balance Sheet Account Details - Additional Information (Details) - USD ($) $ in Thousands	Oct. 06, 2017	May 16, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization expense			$ 16,100	$ 9,500	$ 10,200
Goodwill			337,028	83,834
Depreciation and amortization			14,600	13,400	12,700
Capitalized Software Costs
Finite-Lived Intangible Assets [Line Items]
Amortization expense			$ 800	$ 500	$ 600
Triage Business
Finite-Lived Intangible Assets [Line Items]
Cash consideration	$ 399,798
Goodwill	$ 245,531
RPS Diagnostics
Finite-Lived Intangible Assets [Line Items]
Cash consideration		$ 13,700
Goodwill		7,600
RPS Diagnostics | Technology-Based Intangible Assets
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangibles		$ 6,100

Balance Sheet Account Details36

Balance Sheet Account Details - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 22,252	$ 9,297
Work-in-process (materials, labor and overhead)	22,813	7,990
Finished goods (materials, labor and overhead)	22,013	8,758
Total inventories	$ 67,078	$ 26,045

Balance Sheet Account Details37

Balance Sheet Account Details - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 144,260	$ 121,309
Less: accumulated depreciation and amortization	82,675	70,451
Property, Plant and Equipment, Net	61,585	50,858
Equipment, furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	75,728	61,972
Building and improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	34,994	34,243
Leased instruments
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	32,458	24,014
Land
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 1,080	$ 1,080

Balance Sheet Account Details -

Balance Sheet Account Details - Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 337,028	$ 83,834
Goodwill, Acquired During Period	$ 253,200
Accumulated amortization		(72,562)	(56,367)
Total		203,827
Gross assets		276,389	84,006
Net		$ 203,827	27,639
Purchased technology
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)		9 years 1 month
Gross assets		$ 112,100	53,600
Accumulated amortization		(49,614)	(41,369)
Total		$ 62,486	12,231
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)		7 years 10 days
Gross assets		$ 122,404	7,157
Accumulated amortization		(10,960)	(5,928)
Total		$ 111,444	1,229
License agreements
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)		9 years 10 months 10 days
Gross assets		$ 6,515	6,009
Accumulated amortization		(3,980)	(3,222)
Total		$ 2,535	2,787
Patent and trademark costs
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)		10 years 9 months
Gross assets		$ 28,740	11,240
Accumulated amortization		(4,917)	(3,522)
Total		$ 23,823	7,718
Software development costs
Finite-Lived Intangible Assets [Line Items]
Weighted-average useful life (years)		5 years
Gross assets		$ 6,630	6,000
Accumulated amortization		(3,091)	(2,326)
Total		$ 3,539	$ 3,674

Balance Sheet Account Details39

Balance Sheet Account Details - Future annual amortization expense (Details) $ in Thousands	Dec. 31, 2017USD ($)
Balance Sheet Related Disclosures [Abstract]
2,018	$ 28,799
2,019	27,542
2,020	27,144
2,021	26,996
2,022	26,472
Thereafter	66,874
Total	$ 203,827

Balance Sheet Account Details40

Balance Sheet Account Details - Other current liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Balance Sheet Related Disclosures [Abstract]
Customer incentives	$ 7,165	$ 3,766
Accrued interest	442	227
Other	5,059	1,104
Total other current liabilities	$ 12,666	$ 5,097

Debt Convertible Senior Notes (

Debt Convertible Senior Notes (Details) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2017USD ($)d	Dec. 31, 2016USD ($)$ / shares	Dec. 31, 2015USD ($)	Dec. 08, 2014USD ($)
Debt Instrument [Line Items]
Convertible Senior Notes, if-converted value excess	$ 1,500	$ 1,500
Interest expense, Convertible Senior Notes, Amortization			$ 5,400
Interest Expense, Debt	3,000	11,000	10,900	$ 10,900
Proceeds from issuance of Term Loan		245,000	0	0
Repurchase of Convertible Debt		(547)
Repayments of Convertible Debt		0	4,459	0
Gain on extinguishment of Convertible Senior Notes		0	(421)	0
3.25% Convertible Senior Notes due 2020 [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Convertible Senior Notes, face amount			$ 172,500		$ 172,500
Convertible Senior Notes, interest rate, stated percentage			3.25%
Debt issuance cost			$ 5,100
Deferred financing costs			$ 4,200
Remaining amortization period of discount on the liability component			6 years
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		900
Debt Instrument, Unamortized Discount	15,356	$ 15,356	$ 20,221
Convertible Senior Notes, conversion ratio		31.1891
Convertible Senior Notes, conversion price (in dollars per share) | $ / shares			$ 32.06
Convertible Senior Notes, threshold trading days | d		20
Convertible Senior Notes, threshold consecutive trading days | d		30
Convertible Senior Notes, threshold percentage of stock price trigger		130.00%
Convertible Senior Notes, threshold consecutive business days		5 years
Debt Instrument, Convertible, Threshold Consecutive Trading Days, Following Consecutive Business Days		5 years
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger, Following Consecutive Business Days		98.00%
Convertible Senior Notes, observation period		25 years
Carrying value of equity component, net of issuance costs	$ 29,211	$ 29,211	$ 29,211		30,700
Interest expense, Convertible Senior Notes, Amortization		5,500		5,300
Interest expense, Convertible Senior Notes		$ 5,400	$ 5,500	$ 5,600
Debt Conversion, Converted Instrument, Rate		100.00%
Debt Instrument, Interest Rate, Effective Percentage	6.90%	6.90%	6.60%
Convertible Senior Notes, fair value disclosures					$ 141,900
Proceeds from issuance of Term Loan		$ 172,500
Fair value of outstanding Convertible Senior Notes	$ 257,245	257,245	$ 165,223
Repurchase of Convertible Debt		5,200
Repayments of Convertible Debt		4,500
Repayments of Debt		4,400
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments		500
Gain on extinguishment of Convertible Senior Notes		(400)
3.25% Convertible Senior Notes due 2020 [Member] | Other Current Assets [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Deferred financing costs	$ 2,090	$ 2,090	$ 2,753

Debt Debt schedule (Details)

Debt Debt schedule (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 08, 2014
Debt Instrument [Line Items]
Less: current portion	$ 10,184	$ 0
Long-term debt	227,394	0
Convertible Debt [Member] | 3.25% Convertible Senior Notes due 2020 [Member]
Debt Instrument [Line Items]
Principal amount of Convertible Senior Notes outstanding	167,314	167,314
Unamortized deferred issuance costs	(15,356)	(20,221)
Unamortized deferred issuance costs		(4,200)
Net carrying amount of liability component	149,868	144,340
Less: current portion	0	0
Long-term debt	149,868	144,340
Carrying value of equity component, net of issuance costs	29,211	29,211	$ 30,700
Fair value of outstanding Convertible Senior Notes	$ 257,245	$ 165,223
Remaining amortization period of discount on the liability component	3 years	4 years

Line of Credit (Detail)

Line of Credit (Detail) - USD ($)	Dec. 31, 2017	Oct. 06, 2017
Line of Credit Facility [Line Items]
Convertible Senior Notes, if-converted value excess	$ 1,500,000
Senior Credit Facility		$ 25,000,000

Debt Senior Credit Agreement (D

Debt Senior Credit Agreement (Details)	Oct. 06, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Secured Debt		$ 245,000,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000,000
Proceeds from issuance of Revolving Credit Facility	10,000,000	10,000,000	$ 0	$ 0
Line of Credit Facility, Additional Borrowing Capacity	50,000,000
Unamortized Debt Issuance Expense		(7,422,000)
Debt, Long-term and Short-term, Combined Amount		237,578,000
Long-term Debt, Current Maturities		(10,184,000)	0
Long-term debt		$ 227,394,000	$ 0
Debt Instrument, Credit Agreement, Loan Prepayments, Percentage Of Excess Cash Flow		50.00%
Consolidated Senior Secured Leverage Ratio		1.25
Consolidated Leverage Ratio, Period One		5
Consolidated Leverage Ratio, Period Two		4.25
Consolidated Leverage Ratio, Period Three		3.50
Consolidated Fixed Charge Coverage Ratio		1.25
Triage Business
Debt Instrument [Line Items]
Secured Debt	$ 245,000,000
Federal Funds Effective Swap Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.005%
Base Rate [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin		2.50%
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin		3.50%
Debt Instrument, Basis Spread on Variable Rate		1.00%
Minimum [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.10%
Minimum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin		1.50%
Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin		2.50%
Maximum [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.50%
Maximum [Member] | Base Rate [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin		2.50%
Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Senior Credit Facility, applicable margin		3.50%

Debt Schedule of Maturities of

Debt Schedule of Maturities of Long-term debt (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Maturities of Long-term debt [Abstract]
2,018	$ 12,250,000	$ 12,250,000
2,019	18,375,000	18,375,000
2,020	24,500,000	24,500,000
2,021	24,500,000	24,500,000
2,022	165,375,000	165,375,000
Total	245,000,000	245,000,000
Interest Expense, Debt	3,000,000	11,000,000	$ 10,900,000	$ 10,900,000
Amortization of Debt Issuance Costs	500,000
Interest Expense, Other		$ 100,000
Amortization of Deferred Loan Origination Fees, Net	$ 40,000

Income Taxes - Components of (B

Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal		$ (615)	$ (117)	$ 948
State		314	246	399
Foreign		57	84	41
Total current (benefit) provision		(244)	213	1,388
Deferred:
Federal		131	(2,545)	(4,624)
State		238	(63)	0
Foreign		4	4	18
Total deferred benefit		373	(2,604)	(4,606)
Provision (benefit) for income taxes	$ (3,218)	$ 129	$ (2,391)	$ (3,218)

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
United States	$ (8,198)	$ (16,426)	$ (9,480)
Foreign	162	227	183
Loss before taxes	$ (8,036)	$ (16,199)	$ (9,297)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 3,924	$ 3,255
Intangible assets	2,935	2,351
Sale-leaseback, net	628	888
Allowance for returns and discounts	5,358	4,043
Stock-based compensation	5,933	10,963
Tax credit carryforwards	5,247	3,430
Other, net	4,580	4,066
Total deferred tax assets	28,605	28,996
Valuation allowance for deferred tax assets	(15,204)	(7,774)
Total deferred tax assets	13,401	21,222
Deferred tax liabilities:
Convertible Senior Notes	(3,633)	(7,592)
Intangible assets	(2,935)	(7,557)
Property, plant and equipment	(7,263)	(6,131)
Deferred Tax Liabilities, Gross	(13,831)	(21,280)
Total deferred tax liabilities	$ (430)	$ (58)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014
Income Taxes Disclosure [Line Items]
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions		$ 631	$ 951	$ 773
Deferred Tax Assets, Valuation Allowance	$ 7,774		15,204	7,774
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			(7,400)
Unrecognized Tax Benefits	8,604	7,684	9,565	8,604	$ 7,065
Federal Net Operating Loss carryforwards			13,000
State Net Operating Loss carryforwards			23,300
Federal alternative minimum tax credit			600
Gross research credits		$ 722	$ 484	979
Cumulative changes in ownership percentage			50.00%
Cumulative changes in ownership period			3 years
Realized upon settlement			50.00%
Unrecognized tax benefits that would impact effective tax rate	6,400		$ 8,100	6,400
Accrued interest and penalties associated with uncertain tax positions	200		300	200
Interest expense, net of accrued interest reversed			0	$ 100
Federal research credits [Member]
Income Taxes Disclosure [Line Items]
Federal research credits			$ 4,300
Federal research credits, expiration date			Dec. 31, 2031
Gross State Research Credits [Member]
Income Taxes Disclosure [Line Items]
Gross research credits			$ 9,800
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount			9,500
Effective Income Tax Rate Reconciliation, Tax Credit, Investment, Amount			$ 300
Federal [Member]
Income Taxes Disclosure [Line Items]
Gross research credits	$ 1,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Tax benefit at statutory tax rate	$ (3,254)	$ (2,812)	$ (5,775)
State tax benefits, net of federal tax benefit	(235)	(239)	(390)
Permanent differences	157	327	129
Federal and state research credits—current year	(722)	(484)	(979)
Accrual of uncertain tax positions	101	142	43
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount		(5,851)
Impact of change in federal and state tax rate on revaluing deferred tax assets	56	3,357	(4)
Change in valuation allowance	756	5,799	4,687
Other	(77)	(110)	(102)
Provision (benefit) for income taxes	$ (3,218)	$ 129	$ (2,391)	$ (3,218)

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance		$ 8,604	$ 7,684
Increases (decreases) related to prior year tax positions	$ (12)	(10)	(10)
Increases related to current year tax positions	631	951	773
Other	0	0	157
Ending balance	$ 7,684	$ 9,565	$ 8,604

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Apr. 23, 2013	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred Bonus Liability		$ 900	$ 500	$ 400
Preferred stock, shares authorized		5,000,000	5,000,000	5,000,000
Preferred stock, shares outstanding			0	0
Weighted- average remaining contractual term, exercisable (in years)		3 years 11 months 25 days
Restricted stock granted (in shares)		349,000	185,000	171,000
Share-based compensation expense recognized		$ 9,061	$ 7,986	$ 7,419
Exercise price of stock (in dollars per share)		$ 18.54	$ 17.49	$ 17.44	$ 16.37
Available for future grant, (in shares)		1,848,000
Deferred period of grants (Condition 1)		1 year
Percentage of premium on amount deferred (Condition 1)		10.00%
Deferred period of grants (Condition 2)		2 years
Percentage of premium on amount deferred (Condition 2)		20.00%
Deferred period of grants (Condition 3)		4 years
Percentage of premium on amount deferred (Condition 3)		30.00%
Minimum percentage of common stock under payroll deductions		10.00%
Fair value of payroll deductions		85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period		6 years
Stock sold under the plan (in shares)		1,272,274
Capital shares reserved for future issuance (In shares)		227,726
Payments for repurchase of common stock		$ 541	$ 20,168	$ 30,934
Stock-based compensation expense		$ 541	$ 20,168	$ 30,934
Exercise of stock options		1,527,000	553,000	168,000
Shares reserved for purchase under ESPP (in shares)		227,726
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted- average remaining contractual term, exercisable (in years)		10 years
Restricted stock granted (in shares)		300,000	200,000	200,000
Performance-based vesting period		4 years
Share-based compensation expense recognized		$ 4,900	$ 2,400	$ 2,000
Employee Deferred Bonus Compensation Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized		$ 100	$ 900	$ 700
2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve under equity incentive plans (in shares)		5,300,000
2010 Plan [Member] | Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance-based vesting period		1 year
Non-employee director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock granted (in shares)		100,000	400,000	500,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of deferred 2011 cash bonus		50.00%
Minimum [Member] | 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of stock (in dollars per share)		$ 8.50
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of deferred 2011 cash bonus		100.00%
Maximum [Member] | 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of stock (in dollars per share)		$ 41.36
Share Repurchase Program, Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments for repurchase of common stock	$ 50,000
Repurchase of available shares under share repurchase program (in shares)			1,152,386	1,397,000
Stock-based compensation expense			$ 19,600	$ 30,400
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 35,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 9,061	$ 7,986	$ 7,419
Weighted-average grant date fair value of stock options granted (in dollars per share)	$ 8.99	$ 6	$ 9.46
Total intrinsic value for options exercised	$ 26,800	$ 4,500	$ 1,600
Total unrecognized compensation expense related to non-vested stock options	$ 7,700
Expected weighted-average period of recognition for unrecognized compensation expense	1 year 10 months 20 days
Maximum contractual term	10 years
Deferred Bonus Liability	$ 900	500	400
Deferred bonus compensation program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	100	900	700
Recorded as a component of accrued payroll and related expenses	900	600
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 4,900	2,400	2,000
Expected weighted-average period of recognition for unrecognized compensation expense	1 year 9 months
Number of restricted share units issued (in shares)	0.1
Total unrecognized compensation expense related to non-vested stock awards	$ 13,300
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 4,100	$ 4,700	$ 4,700

Stock-Based Compensation - Comp

Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 9,061	$ 7,986	$ 7,419
Cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	579	617	581
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,886	1,551	734
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2,129	1,189	1,554
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,467	$ 4,629	$ 4,550

Stock-Based Compensation - Esti

Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Risk-free interest rate	2.30%	1.47%	1.50%
Expected option life (in years)	6 years 7 months 16 days	6 years 7 months 3 days	6 years 2 months 25 days
Volatility rate	36.00%	36.00%	40.00%
Dividend rate	0.00%	0.00%	0.00%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Status of Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance, (in shares)	3,941	3,967	3,607
Granted, number of shares (in shares)	263	677	659
Exercised (in shares)	(1,527)	(553)	(168)
Cancelled (in shares)	(18)	(150)	(131)
Ending balance, (in shares)	2,659	3,941	3,967
Vested and expected to vest, (in shares)	2,574
Exercisable, (in shares)	1,463
Available for future grant, (in shares)	1,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Rollforward]
Beginning balance, weighted average exercise price per share (in dollars per share)	$ 17.49	$ 17.44	$ 16.37
Granted, weighted average exercise price per share (in dollars per share)	22.21	15.48	23.15
Exercised, weighted average exercise price per share (in dollars per share)	16.38	13.76	12.30
Cancelled, weighted average exercise price per share (in dollars per share)	24.91	20.86	23.41
Ending balance, weighted average exercise price per share (in dollars per share)	18.54	$ 17.49	$ 17.44
Vested and expected to vest, weighted average exercise price per share (in dollars per share)	18.51
Exercisable, weighted average exercise price per share (in dollars per share)	$ 17.71
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted- average remaining contractual term, outstanding (in years)	5 years 8 months 10 days
Weighted- average remaining contractual term, vested and expected to vest (in years)	5 years 7 months 10 days
Weighted- average remaining contractual term, exercisable (in years)	3 years 11 months 25 days
Aggregate intrinsic value, outstanding	$ 65,969
Aggregate intrinsic value, vested and expected to vest	63,914
Aggregate intrinsic value, available for future grant	$ 37,503

Stock-Based Compensation - Su57

Stock-Based Compensation - Summary of Status of Stock Awards Activity (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning Balance (in shares)	501	459	402
Granted (in shares)	349	185	171
Vested (in shares)	(100)	(120)	(96)
Forfeited (in shares)	(4)	(23)	(18)
Ending Balance (in shares)	746	501	459
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Rollforward]
Beginning Balance, Weighted Average Grant Date Fair Value (in dollars per share)	$ 20.37	$ 21.61	$ 14.84
Granted, Weighted Average Grant Date Fair Value (in dollars per share)	22.34	16.14	22.79
Vested, Weighted Average Grant Date Fair Value (in dollars per share)	23.49	18.50	18.01
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)	18.69	20.80	22.87
Ending Balance, Weighted Average Grant Date Fair Value (in dollars per share)	$ 20.88	$ 20.37	$ 21.61

Earnings (Loss) Per Share (Deta

Earnings (Loss) Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted Average Number of Shares Outstanding, Basic and Diluted	33,734	32,708	34,104
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,400	800	1,000
Weighted Average Number of Shares Outstanding, Diluted	33,734	32,708	34,104
Equity Option and Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	0	0
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	37	2,770	1,902

Commitments and Contingencies -

Commitments and Contingencies - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) $ in Thousands	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, 2017	$ 8,638
Operating Leases, 2018	9,072
Operating Leases, 2019	9,212
Operating Leases, 2020	9,050
Operating Leases, 2021	7,412
Operating Leases, Thereafter	80,559
Operating Leases, Minimum Payments, Total	123,943
Lease Obligation, 2017	946
Lease Obligation, 2018	956
Lease Obligation, 2019	967
Lease Obligation, 2020	0
Lease Obligation, 2021	0
Lease Obligation, Thereafter	0
Lease Obligation, Minimum Payments, Total	$ 2,869

Commitments and Contingencies60

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2015USD ($)ft²	Dec. 31, 2017USD ($)Lease	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)ft²
Sale Leaseback Transaction [Line Items]
Rent expense under operating leases	$ 2,300	$ 2,100	$ 2,200
Lease expiration year		2,022
Number of extension | Lease		2
Extend the lease options		5 years
Lease incentives for tenant improvements		$ 1,700
Facility sold		15,000
Capital contributed		3,800
Cash transaction, netting		$ 7,000
Partnership that acquired the facility		25.00%
Lease payments		$ 900	900	$ 1,100
Purchase Commitment, Remaining Minimum Amount Committed		5,900
Accrued in other current liabilities		12,666	5,097
Amortization expense		16,100	9,500	10,200
Company had royalty and license expenses relating to those agreements		$ 600	$ 800	$ 500
San Diego [Member]
Sale Leaseback Transaction [Line Items]
Lease term period		Dec. 1, 2019
Number of extension | Lease		3
Extend the lease options		5 years
Amended terms		10 years
Property Subject to Operating Lease [Member]
Sale Leaseback Transaction [Line Items]
Area under new operating lease | ft²	30,000			30,000

Commitments and Contingencies C

Commitments and Contingencies Contingent Consideration (Acquisitions) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition, Contingent Consideration [Line Items]
Current portion of contingent consideration	$ 6,293	$ 2,826
Contingent consideration non-current portion	18,008	2,349
Bio Helix
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration—BNP Business	4,600	5,200
Fair Value, Inputs, Level 3 [Member]
Business Acquisition, Contingent Consideration [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	$ 80	$ 500	$ 100

Industry and Geographic Infor62

Industry and Geographic Information - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)Segment	Dec. 31, 2016USD ($)	Dec. 31, 2015
Revenue, Major Customer [Line Items]
Number of reportable segments | Segment	1
Customer Concentration Risk [Member] | Non-U.S. Customers [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	$ 18.8	$ 6.8
Customer Concentration Risk [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	54.00%	44.00%	48.00%
Customer Concentration Risk [Member] | Sales [Member] | Non-U.S. Customers [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	18.00%	17.00%	14.00%
Credit Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	$ 44.4	$ 13.9
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Minimum [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	10.00%	10.00%

Industry and Geographic Infor63

Industry and Geographic Information - Sales to Individual Customers in Excess of 10% of Total Revenue (Detail) - Sales [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue, Major Customer [Line Items]
Sales percentage	54.00%	44.00%	48.00%
Customer A [Member]
Revenue, Major Customer [Line Items]
Sales percentage	21.00%	16.00%	20.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Sales percentage	20.00%	15.00%	17.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Sales percentage	13.00%	13.00%	11.00%

Industry and Geographic Infor64

Industry and Geographic Information - Long-lived Assets (Excluding Intangible Assets) and Total Net Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	$ 61,585				$ 50,858				$ 61,585	$ 50,858
Total revenues	114,890	$ 50,894	$ 38,267	$ 73,692	52,808	$ 49,341	$ 39,133	$ 50,321	277,743	191,603	$ 196,129
Federal [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	59,833				50,774				59,833	50,774
Total revenues									227,611	158,244	168,809
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total	$ 1,752				$ 84				1,752	84
Total revenues									$ 50,132	$ 33,359	$ 27,320

Industry and Geographic Infor65

Industry and Geographic Information - Consolidated Net Product Revenues by Disease State (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenues	$ 277,743	$ 191,603	$ 196,129
Infectious Disease [Member]
Segment Reporting Information [Line Items]
Revenues	165,099	121,416	130,348
Women's Health [Member]
Segment Reporting Information [Line Items]
Revenues		0	0
Gastrointestinal Disease [Member]
Segment Reporting Information [Line Items]
Revenues	51,978	60,681	60,358
Royalty, License Fees and Grant Revenue [Member]
Segment Reporting Information [Line Items]
Revenues	$ 13,636	$ 9,506	$ 5,423

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets:
Total assets at fair value	$ 36,086
Liabilities:
Total liabilities at fair value	247,459	$ 5,175
Cash equivalents
Assets:
Total assets at fair value	36,086	133,540
Contingent consideration
Liabilities:
Total liabilities at fair value	24,301	5,175
Deferred consideration
Liabilities:
Total liabilities at fair value	223,158	0
Level 1 [Member]
Assets:
Total assets at fair value		133,540
Liabilities:
Total liabilities at fair value	0	0
Level 1 [Member] | Cash equivalents
Assets:
Total assets at fair value	36,086	133,540
Level 1 [Member] | Contingent consideration
Liabilities:
Total liabilities at fair value	0	0
Level 1 [Member] | Deferred consideration
Liabilities:
Total liabilities at fair value	0	0
Level 2 [Member]
Assets:
Total assets at fair value	0	0
Liabilities:
Total liabilities at fair value	223,158	0
Level 2 [Member] | Cash equivalents
Assets:
Total assets at fair value	0	0
Level 2 [Member] | Contingent consideration
Liabilities:
Total liabilities at fair value	0	0
Level 2 [Member] | Deferred consideration
Liabilities:
Total liabilities at fair value	223,158	0
Level 3 [Member]
Assets:
Total assets at fair value	0	0
Liabilities:
Total liabilities at fair value	24,301	5,175
Level 3 [Member] | Cash equivalents
Assets:
Total assets at fair value	0	0
Level 3 [Member] | Contingent consideration
Liabilities:
Total liabilities at fair value	24,301	5,175
Level 3 [Member] | Deferred consideration
Liabilities:
Total liabilities at fair value	$ 0	$ 0

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 06, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	$ 36,086	$ 36,086
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	256,000	256,000
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction			$ 0	$ 0
Accretion of interest on deferred consideration	2,608		0	0
Total liabilities at fair value	247,459	247,459	5,175
Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	36,086	36,086	133,540
Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities at fair value	24,301	24,301	5,175
Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities at fair value	223,158	223,158	0
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value			133,540
Total liabilities at fair value	0	0	0
Level 1 [Member] | Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	36,086	36,086	133,540
Level 1 [Member] | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities at fair value	0	0	0
Level 1 [Member] | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities at fair value	0	0	0
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	0	0	0
Total liabilities at fair value	223,158	223,158	0
Level 2 [Member] | Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	0	0	0
Level 2 [Member] | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities at fair value	0	0	0
Level 2 [Member] | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities at fair value	223,158	223,158	0
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings		80	500	$ 100
Total assets at fair value	0	0	0
Total liabilities at fair value	24,301	24,301	5,175
Level 3 [Member] | Cash equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets at fair value	0	0	0
Level 3 [Member] | Contingent consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities at fair value	24,301	24,301	5,175
Level 3 [Member] | Deferred consideration
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities at fair value	0	0	0
Triage Business
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	280,000	280,000
Contingent consideration—BNP Business					$ 19,700
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction		220,550
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		19,700
Bio Helix
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Contingent consideration—BNP Business	$ 4,600	$ 4,600	$ 5,200

Fair Value Measurement - Change

Fair Value Measurement - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Detail) - Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ 5,175
Cash payments	(498)
Net gain recorded for fair value adjustments	(80)	$ (500)	$ (100)
Unrealized loss on foreign currency translation	4
Balance		$ 5,175
Contingent consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ 24,301

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Compensation Related Costs [Abstract]
Pay contributed by employer	50.00%
Pay contributed by employee	6.00%
Contribution to 401 (K) Plan	$ 1.5	$ 1.5	$ 1.3

- Additional Information (Detai

- Additional Information (Detail) $ in Thousands	Oct. 06, 2017USD ($)payment	Dec. 31, 2017USD ($)payment	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Business Acquisition [Line Items]
Secured Debt		$ 245,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		256,000
Deferred consideration for acquisition of BNP Business			$ 0	$ 0
Triage Business
Business Acquisition [Line Items]
Cash consideration	$ 399,798
Secured Debt	245,000
Contingent consideration—BNP Business	19,700
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		280,000
Deferred consideration for acquisition of BNP Business		220,550
Change in amount of contingent consideration, liability		19,700
Consideration A [Member] | Triage Business
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	$ 16,000
Contingent consideration—BNP Business		24,000
Business Combination, Contingent Consideration Arrangements, Number Of Installment Payments | payment	5
Business Combination, Contingent Consideration Arrangements, Amount Of Installment Payment	$ 8,000
Consideration B [Member] | Triage Business
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 240,000
Business Combination, Contingent Consideration Arrangements, Number Of Installment Payments | payment		6
Business Combination, Contingent Consideration Arrangements, Amount Of Installment Payment		$ 40,000
Consideration C [Member] | Triage Business
Business Acquisition [Line Items]
Inventory related adjustment	$ 205

Acquisition - Consideration (De

Acquisition - Consideration (Details) - USD ($) $ in Thousands	Oct. 06, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Deferred consideration for acquisition of BNP Business			$ 0	$ 0
Net consideration		$ 14,451	$ 5,061	$ 0
Triage Business
Business Acquisition [Line Items]
Cash consideration	$ 399,798
Deferred consideration for acquisition of BNP Business		$ 220,550
Contingent consideration—BNP Business	19,700
Net consideration	$ 640,253

Acquisition - Purchase price al

Acquisition - Purchase price allocation (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Oct. 06, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 337,028		$ 83,834
Triage Business
Business Acquisition [Line Items]
Prepaid expenses and other current assets		$ 796
Assets held for sale		146,540
Inventories		52,205
Property, plant and equipment		10,608
Intangible assets		184,900
Goodwill		245,531
Other non-current assets		182
Total assets acquired		640,762
Other current liabilities		(509)
Total net assets and liabilities acquired		$ 640,253

Acquisition - Intangible assets

Acquisition - Intangible assets acquired (Details) - USD ($) $ in Thousands	Oct. 06, 2017	Dec. 31, 2017
Triage Business
Business Acquisition [Line Items]
Intangible Asset	$ 184,900
Purchased technology
Business Acquisition [Line Items]
Weighted-average useful life (years)		9 years 1 month
Purchased technology | Triage Business
Business Acquisition [Line Items]
Intangible Asset	$ 52,400
Weighted-average useful life (years)	10 years
Customer relationships
Business Acquisition [Line Items]
Weighted-average useful life (years)		7 years 10 days
Customer relationships | Triage Business
Business Acquisition [Line Items]
Intangible Asset	$ 115,000
Weighted-average useful life (years)	7 years
Trademarks | Triage Business
Business Acquisition [Line Items]
Intangible Asset	$ 17,500
Weighted-average useful life (years)	10 years

Acquisition - Pro forma informa

Acquisition - Pro forma information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Revenues	$ 277,743	$ 191,603	$ 196,129
Acquisition and integration costs	16,506	711	2,390
Amortization of inventory step-up to fair value	10,950	0	0
Triage Business
Business Acquisition [Line Items]
Pro forma total revenues	468,577	437,525
Pro forma net income	$ 41,296	$ 28,045
Pro forma basic earnings per share	$ 1,220	$ 860
Pro forma diluted net earnings per share	$ 1,180	$ 840
Net loss included in the Consolidated Statement of Operations since acquisition	$ (4,776)
Acquisition and integration costs	11,700
Amortization of inventory step-up to fair value	11,000
Molecular
Business Acquisition [Line Items]
Revenues		$ 0	$ 0
Molecular | Triage Business
Business Acquisition [Line Items]
Revenues	$ 47,030

Selected Quarterly Financial 75

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Total revenues	$ 114,890	$ 50,894	$ 38,267	$ 73,692	$ 52,808	$ 49,341	$ 39,133	$ 50,321	$ 277,743	$ 191,603	$ 196,129
Cost of sales									121,601	79,872	78,029
Gross profit	59,127	29,690	18,826	48,499	32,001	30,023	20,225	29,482	156,142	111,731	118,100
Operating Income (Loss)	3,887	(2,537)	(11,027)	19,229	5,915	2,125	(9,019)	(3,460)	9,552	(4,439)	2,738
Net loss	$ (5,088)	$ (5,525)	$ (11,842)	$ 14,290	$ (1,950)	$ (572)	$ (7,840)	$ (3,446)	$ (8,165)	$ (13,808)	$ (6,079)
Basic and diluted loss per share	$ (0.15)	$ (0.16)	$ (0.35)	$ 0.43	$ (0.06)	$ (0.02)	$ (0.24)	$ (0.11)
Diluted net earnings (loss) per share	$ (0.15)	$ (0.16)	$ (0.35)	$ 0.42

Selected Quarterly Financial 76

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Footnote) (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended								9 Months Ended	12 Months Ended				50 Months Ended
	Jul. 31, 2016	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2016
Income Statement [Abstract]
Prior Period Reclassification Adjustment	$ 0.6				$ 6.5	$ 0.7	$ 0.7		$ 2.5		$ 2.6	$ 0.7	$ 6.3	$ 2.4	$ 0.6
prior year reclassification of amortization		$ 1.8	$ 1.7	$ 1.6	$ 1.7	$ 1.6	$ 1.6	$ 1.6		$ 0.7

Consolidated Valuation and Qu77

Consolidated Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]
Ending Balance	$ 1,800
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	7,165	$ 7,488	$ 8,221
Additions charged to expense or as reductions to revenue	36,449	28,329	31,532
Deductions	(31,305)	(28,652)	(32,265)
Ending Balance	$ 12,309	$ 7,165	$ 7,488

Subsequent Events (Details)

Subsequent Events (Details) $ in Thousands	Jan. 11, 2018USD ($)	Jan. 05, 2018USD ($)building	Oct. 06, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Subsequent Event [Line Items]
Secured Debt				$ 245,000
Assets Held-for-sale, Not Part of Disposal Group, Current				146,644	$ 0
Proceeds from issuance of Revolving Credit Facility			$ 10,000	$ 10,000	$ 0	$ 0
Subsequent Event
Subsequent Event [Line Items]
Proceeds from Sale of Property, Plant, and Equipment		$ 146,600
Sale Leaseback Transaction, Number Of Buildings | building		2
Sale Leaseback Transaction, Lease Terms		P15Y
Repayments of Debt	$ 100,000
Secured Debt	145,000
Repayments of Lines of Credit	$ 10,000